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A B S T R A C T
Background
Nausea, retching and vomiting are very commonly experienced by women in early pregnancy. There are considerable physical and
psychological effects on women who experience these symptoms. This is an update of a review of interventions for nausea and vomiting
in early pregnancy previously published in 2003.
Objectives
To assess the effectiveness and safety of all interventions for nausea, vomiting and retching in early pregnancy, up to 20 weeks’ gestation.
Search methods
We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register (28 May 2010).
Selection criteria
All randomised controlled trials of any intervention for nausea, vomiting and retching in early pregnancy. We excluded trials of
interventions for hyperemesis gravidarum which are covered by another review. We also excluded quasi-randomised trials and trials
using a crossover design.
Data collection and analysis
Four review authors, in pairs, reviewed the eligibility of trials and independently evaluated the risk of bias and extracted the data for
included trials.
Main results
Twenty-seven trials, with 4041 women, met the inclusion criteria. These trials covered many interventions, including acupressure,
acustimulation, acupuncture, ginger, vitamin B6 and several antiemetic drugs. We identified no studies of dietary or other lifestyle
interventions. Evidence regarding the effectiveness of P6 acupressure, auricular (ear) acupressure and acustimulation of the P6 point
was limited. Acupuncture (P6 or traditional) showed no significant benefit to women in pregnancy. The use of ginger products may
be helpful to women, but the evidence of effectiveness was limited and not consistent. There was only limited evidence from trials
to support the use of pharmacological agents including vitamin B6, and anti-emetic drugs to relieve mild or moderate nausea and
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vomiting. There was little information on maternal and fetal adverse outcomes and on psychological, social or economic outcomes.
We were unable to pool findings from studies for most outcomes due to heterogeneity in study participants, interventions, comparison
groups, and outcomes measured or reported. The methodological quality of the included studies was mixed.
Authors’ conclusions
Given the high prevalence of nausea and vomiting in early pregnancy, health professionals need to provide clear guidance to women,
based on systematically reviewed evidence. There is a lack of high-quality evidence to support that advice. The difficulties in interpreting
the results of the studies included in this review highlight the need for specific, consistent and clearly justified outcomes and approaches
to measurement in research studies.
P L A I N L A N G U A G E S U M M A R Y
Interventions for nausea and vomiting in early pregnancy
Nausea, retching or dry heaving, and vomiting in early pregnancy are very common and can be very distressing for women. Many
treatments are available to women with “morning sickness”, including drugs and complementary and alternative therapies. This review
aimed to examine if these treatments have been found to be effective and safe because of the concern that taking medications may
adversely affect the development of the fetus.
This review found a lack of high-quality evidence to back up any advice on which interventions to use. We examined 27 randomised
controlled trials which included 4041 women in early pregnancy. These studies examined the effectiveness of many treatments including
acupressure to the acupuncture point on the wrist (P6), acustimulation, acupuncture, ginger, vitamin B6 and several conventional drugs
that are used to reduce nausea or vomiting. Some studies showed a benefit in improving nausea and vomiting symptoms for women,
but generally effects were inconsistent and limited. Studies were carried out in a way that meant they were at high risk of bias, and
therefore, it was difficult to draw firm conclusions. Most studies had different ways of measuring the symptoms of nausea and vomiting
and therefore, we could not look at these findings together. Few studies reported maternal and fetal adverse outcomes and there was
very little information on the effectiveness of treatments for improving women’s quality of life.
B A C K G R O U N D
Nausea and vomiting are commonly experienced by women in
early pregnancy. Prevalence rates of between 50% and 80% are
reported for nausea, and rates of 50% for vomiting and retching (
Miller 2002;Woolhouse 2006). Retching (or dry heaving, without
expulsionof the stomach’s contents) has beendescribed as a distinct
symptom that is increasingly measured separately to vomiting and
nausea (Lacasse 2008; O’Brien 1996; Zhou 2001).
The misnomer ’morning sickness’, which is colloquially used to
describe nausea, vomiting and retching of pregnancy, belies the
fact that symptoms can occur at any time of the day. Pregnant
women experience nausea, vomiting and retching mostly in the
first trimester, between six and 12 weeks, but this can continue
to 20 weeks and persists after this time for up to 20% of women
(Jewell 2003; Miller 2002).
Hyperemesis gravidarum,which is characterised by severe and per-
sistent vomiting, is less common, affecting between 0.30% and
3% of pregnant women (Eliakim 2000; Jewell 2003;Miller 2002).
Hyperemesis gravidarum is defined in different ways, though a
widely used definition describes it as “intractable vomiting asso-
ciated with weight loss of more than 5% of prepregnancy weight,
dehydration and electrolyte imbalances which may lead to hospi-
talization” (Miller 2002). Ketosis is also commonly included as a
consequence of hyperemesis gravidarum (Kousen 1993; Quinlan
2003). Including inpatient hospitalisation in the definition of hy-
peremesis gravidarum is problematic (Swallow 2002) as some in-
stances may be alleviated or controlled by outpatient interventions
(Bsat 2003). Within the operational definitions of hyperemesis
gravidarum, there is generally a focus on the effects of the vom-
iting (dehydration, ketosis, weight loss). The lack of a standard
definition has implications for the measurement of outcomes in
controlled studies.
It is important to exclude pathological causes of nausea and vom-
iting before concluding that this is specific to pregnancy. Preg-
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nant women being treated for nausea, vomiting and retching of
pregnancy should have the other pathological causes of nausea
and vomiting (such as peptic ulcers, cholecystitis, gastroenteri-
tis, appendicitis, hepatitis, genito-urinary (e.g. pyelonephritis),
metabolic and neurological disorders) considered and excluded
before a diagnosis of nausea, vomiting and retching of pregnancy
is given (Davis 2004; Koch 2002; Quinlan 2003).
Thought to be associated with rising levels of human chori-
onic gonadotropin (hCG) or estrogens, the causes of nausea,
vomiting and retching of pregnancy remain unknown (Goodwin
2002). Vestibular, gastrointestinal, olfactory and behavioural fac-
tors may influence the woman’s response to the hormonal changes
(Goodwin 2002). Social, psychological and cultural influencing
factors have also been studied (Buckwalter 2002; O’Brien 1999).
The number of previous pregnancies and the number of fetuses
both seem to affect the risk of nausea and vomiting of pregnancy
(Einarson 2007; Louik 2006). Conditions with higher levels of
hCG (multiple pregnancies and molar pregnancies (hydatidiform
mole)) have been associated with more prevalent and more severe
nausea and vomiting of pregnancy. Based on observational studies,
nausea, vomiting and retching in the first trimester were thought
to be associated with a decreased risk of miscarriage, preterm de-
livery, low birthweight, stillbirth and fetal and perinatal mortal-
ity (Czeizel 2004; Weigel 1989) although a later study challenged
these claims (Louik 2006).
There are considerable physical and psychological effects on
women who experience these symptoms, with altered family, so-
cial or occupational functioning (Attard 2002; Chou 2003; Chou
2008; O’Brien 1992; O’Brien 1997; Swallow 2004). Nausea and
vomiting affect women’s daily activities and their relationships
(Atanackovic 2001; Attard 2002; Magee 2002b). The distress and
functional limitations caused by nausea without vomiting are in-
creasingly acknowledged (Davis 2004).Womenhave reported that
theywould like their symptoms and ensuingdistress acknowledged
to a greater degree by health professionals (Locock 2008). Studies
have also highlighted the economic burden on women and society,
mainly due to lost productivity and healthcare costs (Attard 2002;
Piwko 2007).
Women are commonly offered advice about the (usually) self-lim-
iting nature of the condition and advised to avoid foods, smells,
activities or situations that they find nauseating and to eat small
frequent meals of dry, bland foodstuffs (Davis 2004; Ornstein
1995). Many remedies are suggested for nausea and vomiting in
early pregnancy, including pharmaceutical and non-pharmaceuti-
cal interventions.
Pharmaceutical treatments include anticholinergics, antihis-
tamines, dopamine antagonists, vitamins (B6 and B12), H3 antag-
onists or combinations of these substances (Koren 2002a; Kousen
1993;Magee 2002a; Quinlan 2003). The teratogenic effects (abil-
ity to disturb the growth or development of the embryo or fetus) of
pharmaceutical medications (such as thalidomide) used in the past
to control these symptoms have led to caution about prescribing
and taking medications in the first trimester. This has led to the
under-use of drugs that have been found to be safe and effective,
for example, Bendecitin/Diclectin (doxylamine and pyridoxine)
(Koren 2002a; Ornstein 1995). This drug was withdrawn from
the US market because of the legal costs associated with its de-
fence, despite its record of safety and a lack of legal rulings against
it (Brent 2002; Koren 2002a; Ornstein 1995).
Because of concern about pharmaceuticals in early pregnancy and
the general rise in the use of complementary and alternative thera-
pies, non-pharmaceutical treatments are increasingly used to treat
nausea and vomiting in pregnancy, because they may be perceived
as ’natural’ and therefore safe or lower risk thanmedications. These
include herbal remedies (ginger, chamomile, peppermint, rasp-
berry leaf ), acupressure, acustimulation bands and acupuncture,
relaxation, autogenic feedback training, homeopathic remedies
(nux vomica, pulsatilla), massage, hypnotherapy, dietary interven-
tions, activity interventions, emotional support, psychological in-
terventions and behavioural interventions/modifications (Aikins
Murphy 1998; Davis 2004; Jewell 2003; Niebyl 2002; Wilkinson
2000).
Studies report that healthcare professionals frequently recommend
non-pharmaceutical treatments (Bayles 2007; Westfall 2004) and
women frequently use them (Ernst 2002b; Tiran 2002). Along-
side this growth in their use, there are concerns about the effi-
cacy and safety of non-pharmaceutical treatments (Ernst 2002a;
Ernst 2002b; Tiran 2002; Tiran 2003), as they are less rigorously
regulated than pharmaceutical remedies. In addition, women and
professionals are more likely to underestimate their possible risks
(Tiran 2002; Tiran 2003).
O B J E C T I V E S
To assess the effectiveness and safety of all interventions for nau-
sea, vomiting and retching in early pregnancy, up to 20 weeks’
gestation.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included all randomised controlled trials of any intervention
for nausea, vomiting and retching in early pregnancy. However,
we excluded trials of interventions for hyperemesis gravidarum,
which are being covered by another Cochrane review, the protocol
3Interventions for nausea and vomiting in early pregnancy (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
for which is currently being prepared.We have not included quasi-
randomised trials and trials using a crossover design. We have
included studies reported in abstracts only, provided that there
was sufficient information in the abstract, or available from the
author, to allow us to assess eligibility and risk of bias.
Types of participants
Women experiencing nausea, vomiting and/or retching in preg-
nancy (but not hyperemesis gravidarum), where recruitment to a
trial took place up to 20 weeks’ gestation.
Types of interventions
We included all interventions for nausea, vomiting and/or retch-
ing.
Types of outcome measures
Primary outcomes
Symptomatic relief
Reduction or cessation in nausea, vomiting and/or retching.
We examined outcomes measured by all commonly used instru-
ments, including the following.
• Pregnancy-Unique Quantification of Emesis and Nausea
(PUQE), comprising three subscales covering nausea, vomiting
and retching during the past 12 hours, measured using a five-
point Likert scale; possible range three to 15, representing no
symptoms to maximal symptoms; the cut-off point for severe
symptoms is 13. This scale was developed by clinician-
researchers at the Canadian Motherisk Program (Koren 2002a)
studying nausea and vomiting in pregnancy and validated using
the Rhodes Index (see next paragraph) and independent variables
(Koren 2002b; Koren 2005; Lacasse 2008).
• The Rhodes Index of Nausea, Vomiting and Retching
(three subscales: nausea, vomiting and retching, eight items,
measures levels and distress caused by these; possible score range
is eight to 40 representing no symptoms to maximal symptoms;
the cut-off point for severe symptoms is 33. Originally created by
Rhodes (Rhodes 1984) to measure the nausea and vomiting
symptoms associated with chemotherapy, this index has been
validated in studies of nausea and vomiting of pregnancy
(O’Brien 1996; Zhou 2001).
• McGill Nausea Questionnaire: measures nausea only. This
questionnaire includes a qualitative measure (sets of verbal,
affective and other descriptors of nausea); a nausea rating index
(nine sets of words ranked in order of increasing severity); an
overall nausea index; and a visual analogue scale (no nausea to
extreme nausea, 10 cm scale). Developed by Melzack for cancer
chemotherapy and validated for use in studies of nausea and
vomiting in pregnancy (Lacroix 2000; Melzack 1985).
• Nausea and Vomiting of Pregnancy Instrument: includes
three questions, one each about nausea, vomiting and retching in
the past week; possible range is zero to15; the cut-off point for
severe symptoms is 8. Reliability and validity have been
adequately described (Swallow 2002; Swallow 2005).
• Visual analogue scales (graded 0 to 10) to record severity of
nausea (Can Gurkan 2008; Pongrojpaw 2007; Vutyavanich
1995).
The primary outcome of reduction in symptoms, encompasses
non-worsening of symptoms (including up to those of hyperemesis
gravidarum).
Adverse maternal and fetal/neonatal outcomes
Adverse fetal/neonatal outcomes
• Fetal or neonatal death. This includes spontaneous
abortion, stillbirth (death of a fetus of at least 500 g weight or
before 20 weeks’ gestation); neonatal death (death of a baby born
alive, within 28 days of birth).
• Congenital abnormalities (an abnormality of prenatal
origin, including structural, genetic and/or chromosomal
abnormalities and biochemical defects, but not including minor
malformations that do not require medical treatment) (South
Australian Health Commission 1999; Zhou 1999).
• Low birthweight (less than 2.5 kg).
• Early preterm birth (before 34 weeks’ gestation).
Adverse maternal outcomes
• Pregnancy complications (antepartum haemorrhage,
hypertension, pre-eclampsia (hypertension ≥ 140/90 mm Hg
(millimetres of mercury), proteinuria ≥ 0.3 g/L from the 20th
week of pregnancy).
Secondary outcomes
Quality of life
Quality of life outcomes encompass emotional, psychological,
physical well-being; women’s assessment of the pregnancy experi-
ence; women’s ability to cope with the pregnancy. Measured us-
ing the General Health Questionnaire (GHQ) and other generic
Quality of Life (QoL) and other well-being (mental health) and
copingmeasures (Attard 2002;Chou 2003; Lacasse 2008; Swallow
2004; Swallow 2005) and a validated pregnancy-specific Quality
of Life instrument (Magee 2002b).
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Economic costs
• Direct financial costs to women (purchase of treatments).
• Productivity costs (time off work).
• Healthcare system costs (provision of services, consultation
time, staff time) (Attard 2002; Koren 2005; Piwko 2007).
Search methods for identification of studies
Electronic searches
We searched the Cochrane Pregnancy and Childbirth Group’s Tri-
als Register by contacting the Trials Search Co-ordinator (28 May
2010).
The Cochrane Pregnancy and Childbirth Group’s Trials Register
is maintained by the Trials Search Co-ordinator and contains trials
identified from:
1. quarterly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE;
3. handsearches of 30 journals and the proceedings of major
conferences;
4. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Details of the search strategies for CENTRAL and MEDLINE,
the list of handsearched journals and conference proceedings, and
the list of journals reviewed via the current awareness service can
be found in the ‘Specialized Register’ section within the edito-
rial information about the Cochrane Pregnancy and Childbirth
Group.
Trials identified through the searching activities described above
are each assigned to a review topic (or topics). The Trials Search
Co-ordinator searches the register for each review using the topic
list rather than keywords.
Because of the non-pharmaceutical interventions which are rec-
ommended for nausea and vomiting in early pregnancy, we also li-
aised with the Cochrane Complementary Medicine Field to iden-
tify any other trials.
We did not apply any language restrictions.
Data collection and analysis
Selection of studies
Two review authors independently assessed for inclusion all the
potential studies we identified as a result of the search strategy. We
resolved any disagreement through discussion or, if required, we
consulted a third review author.
Data extraction and management
We designed a form to extract data. For eligible studies, two re-
view authors extracted the data using the agreed form.We resolved
discrepancies through discussion or, if required, we consulted a
third review author. We entered data into Review Manager soft-
ware (RevMan 2008) and checked them for accuracy.
When information regarding any of the above was unclear, we
attempted to contact authors of the original reports to provide
further details.
Assessment of risk of bias in included studies
Two review authors independently assessed risk of bias for each
study using the criteria outlined in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2009). We resolved
any disagreement by discussion or by involving a third assessor.
(1) Sequence generation (checking for possible selection
bias)
Wedescribed for each included study themethods used to generate
the allocation sequence in order to assess whether the process was
truly random. We assessed the methods as:
• adequate (e.g. random-number table; computer random
number generator);
• inadequate (odd or even date of birth; hospital or clinic
record number);
• unclear.
(2) Allocation concealment (checking for possible selection
bias)
We described for each included study the method used to con-
ceal the allocation sequence and determined whether intervention
allocation could have been foreseen in advance of, or during, re-
cruitment, or changed after assignment.
We assessed the methods as:
• adequate (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• inadequate (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear.
(3) Blinding (checking for possible performance bias)
We have described for each included study all the methods used, if
any, to blind study participants and personnel from knowledge of
which intervention a participant received. We have also provided
information relating to whether the intended blinding was effec-
tive if this was available. We have noted where there had been par-
tial blinding (e.g. where it was not feasible to blind participants,
but where outcome assessment was carried out without knowledge
of group assignment).
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We assessed the methods as:
• adequate, inadequate or unclear for participants;
• adequate, inadequate or unclear for personnel;
• adequate inadequate or unclear for outcome assessors.
(4) Incomplete outcome data (checking for possible attrition
bias through withdrawals, dropouts, protocol deviations)
We have described for each included study the completeness of
outcome data for each main outcome, including attrition and ex-
clusions from the analysis. We have stated whether attrition and
exclusions were reported, the numbers included in the analysis at
each stage (compared with the total randomised participants), rea-
sons for attrition/exclusion where reported, and any re-inclusions
in analyses which we undertook.
We assessed the methods as:
• adequate (e.g. where there was little or no missing data and
where reasons for missing data were balanced across groups);
• inadequate (e.g. where missing data were likely to be related
to outcomes or not balanced across groups or where high levels
of missing data were likely to introduce serious bias or make the
interpretation of results difficult);
• unclear (e.g. where there was insufficient reporting of
attrition or exclusions to permit a judgement to be made).
(5) Selective reporting bias
We have described for each included study how the possibility of
selective outcome reporting bias was examined by us and what we
found.
We assessed the methods as:
• adequate (where it was clear that all of the study’s
prespecified outcomes and all expected outcomes of interest to
the review were reported);
• inadequate (where not all the study’s prespecified outcomes
were reported; one or more reported primary outcomes were not
prespecified; outcomes of interest were reported incompletely
and so could not be used; study failed to include results of a key
outcome that would have been expected to have been reported);
• unclear.
(6) Other sources of bias
Wehave described for each included study any important concerns
we have about other possible sources of bias. Potential examples
would include where there was a risk of bias related to the specific
study design, where a trial stopped early due to some data-depen-
dent process, or where there was extreme baseline imbalance.
We assessed whether each study was free of other issues that could
put it at risk of bias and assessed each as:
• adequate;
• inadequate;
• unclear.
(7) Overall risk of bias
Wehavemade explicit judgements about risk of bias for important
outcomes both within and across studies. With reference to (1) to
(6) above we assessed the likely magnitude and direction of the
bias and whether we considered it was likely to impact on the
findings. We have explored the impact of the level of bias through
undertaking sensitivity analyses, see Sensitivity analysis.
Measures of treatment effect
Dichotomous data
For dichotomous data, we have presented results as summary risk
ratio with 95% confidence intervals.
Continuous data
For continuous data, we have used themean difference if outcomes
were measured in the same way between trials. We have used the
standardised mean difference to combine trials that measured the
same outcome, but used different methods.
Unit of analysis issues
We have not included any crossover trials. We did not identify any
cluster-randomised trials on this topic. If we had identified such
trials, and they were otherwise eligible for inclusion, we would
have included and analysed them with individually randomised
trials using the methods set out in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2009).
Dealing with missing data
For included studies, we have noted levels of attrition. We have
explored the impact of including studies with high levels of miss-
ing data in the overall assessment of treatment effect by using sen-
sitivity analysis.
We have analysed data on all participants with available data in the
group to which they were allocated, regardless of whether or not
they received the allocated intervention. If in the original reports
participants were not analysed in the group to which they were
randomised, and there is sufficient information in the trial report,
we have attempted to restore them to the correct group.
For all outcomes we have carried out analyses, as far as possible,
on an intention-to-treat basis, i.e. we have attempted to include
all participants randomised to each group in the analyses. The
denominator for each outcome in each trial is the number ran-
domised minus any participants whose outcomes were known to
be missing.
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Assessment of heterogeneity
We visually examined the forest plots for each analysis to look for
obvious heterogeneity and used the I² and T² statistics to quantify
heterogeneity among the trials. If we identified moderate or sub-
stantial heterogeneity (I² greater than 50% and T² greater than
zero) we used a random-effects model in meta-analyses and have
indicated the values of I² and T² and the P value for the Chi2
test for heterogeneity. For outcomes where there are high levels
of heterogeneity we would advise caution in the interpretation of
results.
Assessment of reporting biases
Where we suspected reporting bias (see ’Selective reporting bias’
above), we attempted to contact study authors asking them to
provide missing outcome data. Where this was not possible, and
we thought that the missing data might introduce serious bias,
we explored the impact of including such studies in the overall
assessment of results by sensitivity analysis.
Data synthesis
We carried out statistical analysis using the Review Manager soft-
ware (RevMan 2008).We used fixed-effect meta-analysis for com-
bining data where trials examined the same intervention, and we
judged the trials’ populations and methods were sufficiently simi-
lar. Where we suspected clinical or methodological heterogeneity
among studies sufficient to suggest that treatment effects might
differ between trials, we used random-effects meta-analysis.
If we identified substantial heterogeneity in a fixed-effect meta-
analysis, we repeated the analysis using a random-effects method.
Subgroup analysis and investigation of heterogeneity
We planned separate subgroup analyses by type of intervention,
where comparability of trials and data allowed.
We planned to use the following primary outcomes in subgroup
analysis.
1. Symptomatic relief (reduction or cessation of nausea,
vomiting and/or retching);
2. adverse fetal and neonatal outcomes;
3. adverse maternal outcomes.
For fixed- and random-effects meta-analyses we planned to assess
differences between subgroups by inspection of the subgroups’
confidence intervals; non-overlapping confidence intervals indi-
cating a statistically significant difference in treatment effect be-
tween the subgroups. In this version of the review data were not
available to carry out planned subgroup analysis.
Sensitivity analysis
We planned to perform sensitivity analyses where appropriate, for
example where there was risk of bias associated with the quality of
some of the included trials, or to explore the effects of fixed-effect
or random-effects analyses for outcomes with statistical hetero-
geneity. However, as studies examined a variety of interventions
we were able to pool only very limited data from a small number
of studies. In updates of the review, if more data become available
we will carry out planned sensitivity analyses.
R E S U L T S
Description of studies
See: Characteristics of included studies; Characteristics of
excluded studies; Characteristics of studies awaiting classification;
Characteristics of ongoing studies.
Results of the search
The search strategy identified 66 reports representing 55 studies
(some of the studies resulted in more than one publication). Of
these 55 studies, 27 met the inclusion criteria for the review, we
excluded 22, four are awaiting further assessment, and two studies
have not been completed yet.
Included studies
The included studies examined a range of interventions.
Acupressure is a noninvasive variation of acupuncture which in-
volves the application of constant pressure to specific points or
areas. P6 (or Neigun point) acupressure is proposed to treat symp-
toms of nausea and vomiting (O’Brien 1996). The P6 point is
located on the medial aspect of the forearm, at a specific point
near the wrist. The effectiveness of acupressure to the P6 acupres-
sure point was examined in five studies; in four of these the use of
acupressure wrist bands was compared with placebo (Belluomini
1994; Norheim 2001; O’Brien 1996; Werntoft 2001), and in one
with vitamin B6 (Jamigorn 2007) (in this study women in both
groups also received a placebo intervention). One study exam-
ined the use of acustimulation to the P6 acupressure point (Rosen
2003). Another study compared auricular (on the ear) acupressure
to placebo (Puangsricharern 2008). Two trials compared acupunc-
ture with sham acupuncture (Knight 2001; Smith 2002); in one
of these (Smith 2002) separate groups received traditional and P6
acupuncture.
The use of ginger (prepared as syrup or capsules) to relieve nausea
was examined in nine studies; in four of these ginger was com-
pared with a placebo preparation (Keating 2002; Ozgoli 2009;
Vutyavanich 2001;Willetts 2003), in one with an anti-emetic (di-
menhydrinate) (Pongrojpaw 2007), and in four studies the com-
parison group received vitamin B6 (Chittumma 2007; Ensiyeh
2009; Smith 2004; Sripramote 2003).
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In two studies the intervention group received vitamin B6 (pyri-
doxine), whichwas comparedwith placebopreparations (Sahakian
1991; Vutyavanich 1995).
One study examined the use of moxibustion compared with tra-
ditional Chinese herbs (Fan 1995).
Six studies examined the use of antiemetic drugs: five compared
placebo tablets with active treatment (fluphenazine (Price 1964),
hydroxyzine hydrochloride (Erez 1971), Bendectin (Bentyl, De-
capryn and pyridoxine) (Geiger 1959) or Debendox (a mixture of
dicyclomine, doxylamine and pyridoxine) (McGuiness 1971), or
thiethylperazine (Newlinds 1964)); one study (Bsat 2003) looked
at the effectiveness of three different anti-emetics (metoclopramide
with vitamin B6, prochlorperazine and promethazine).
All of the studies recruited women with symptoms of nausea (with
or without vomiting) although we specifically excluded studies
focusing on women with hyperemesis gravidarum. The severity
of symptoms was not always made clear, and it is possible that
some of the included studiesmay have recruited somewomenwith
more severe symptoms. One study included separate data for those
women with the most severe nausea and vomiting (Rosen 2003),
though not in a form that allowed us to analyse these separately as
part of subgroup analysis.
The stage of pregnancy at which women were recruited to studies
varied, although predominantly women were recruited during the
first trimester (less than 12 weeks’ gestation). In one study (Fan
1995) women with gestational ages of more than eight weeks were
included, but the upper limit was not specified; one study recruited
women up to 20 weeks (McGuiness 1971), one up to 24 weeks
(O’Brien 1996) and one up to 36 weeks (Price 1964). Although
most of the women in these trials were in the first trimester and
therefore, we did not wish to exclude the studies; separate figures
were not provided on those women with nausea later in pregnancy,
and so we were not able to exclude these women from the analyses.
All of the studies collected outcome data on persistence of nau-
sea symptoms or relief from nausea. Nevertheless, pooling data
from studies was complicated by the variability in the way
outcome data were collected and reported. The Rhodes Index
of Nausea, Vomiting and Retching was used in nine studies
(Belluomini 1994; Chittumma 2007; Jamigorn 2007; O’Brien
1996; Puangsricharern 2008; Rosen 2003; Smith 2002; Smith
2004; Willetts 2003). Not all studies collected or reported data
on all dimensions (duration, frequency, distress) of the three sub-
scales (nausea, vomiting, retching) included in the index. Eight
studies collected ordinal data (Bsat 2003; Erez 1971; Fan 1995;
Geiger 1959; Knight 2001; McGuiness 1971; Newlinds 1964;
Price 1964). In these studies women were asked, for example, to
rate symptoms on a five-point Likert-type scale or to describe the
relief from symptoms on a three-point scale; we have converted
some of the data from studies using such scales into binary data for
incorporating them into the review. In 11 studies a visual analogue
scale (VAS) was used (Keating 2002; Knight 2001 (for overall ef-
fectiveness rating); Ensiyeh 2009; Norheim 2001; Ozgoli 2009;
Pongrojpaw 2007; Sahakian 1991; Sripramote 2003; Vutyavanich
1995; Vutyavanich 2001; Werntoft 2001). The wording on each
VAS differed slightly, though in most cases women were asked to
rate their symptoms on a 10 cm (or 100 mm) line, with 0 repre-
senting no symptom(s) (for example, no nausea) and 10 represent-
ing theworst symptom(s) (for example, the worst possible nausea).
No authors provided details of validity or reliability testing of the
VAS used.
Several studies reported the number of vomiting episodes recorded
by women each day (Bsat 2003; Ensiyeh 2009; Keating 2002;
Ozgoli 2009; Pongrojpaw 2007; Sahakian 1991; Sripramote 2003;
Vutyavanich 1995; Vutyavanich 2001; Werntoft 2001), in addi-
tion to those above that used the Rhodes Index, which also mea-
sures frequency of vomiting. One study measured the use of rescue
medication (Jamigorn 2007), and two others the use of over-the-
counter and prescribed medication (Puangsricharern 2008; Rosen
2003).
In this review we chose to describe outcomes relating to women’s
experience of nausea and vomiting at approximately three days
after the start of treatment, as many of the studies provided data
at this time point. We judged that this was a clinically meaningful
point as most medication and other interventions would be ex-
pected to have achieved some effect within this timeframe. Where
this information was not available, we chose the closest time point
to three days that was reported. In the Characteristics of included
studies tables, we have set out the time points when outcome data
on symptoms were collected and reported in relation to the com-
mencement of treatment. This information is important, as for
many women symptoms are likely to resolve over time with or
without treatment, particularly as the pregnancy progresses be-
yond the first trimester. In studies where outcome data were col-
lected weekly over three or four weeks (e.g. Smith 2002; Smith
2004) we considered that differences between groups would be
more difficult to detect at later follow-up points, and for these
studies we have used symptom data from the earlier assessments
(e.g. after seven days) in the data and analyses tables.
As well as symptomatic relief, our primary outcomes also included
maternal and fetal/neonatal adverse effects. Five studies reported
adverse fetal outcomes (Ensiyeh 2009; Erez 1971; Smith 2002;
Vutyavanich 2001; Willetts 2003). Adverse maternal outcomes
(such as preterm labour or spontaneous abortion)were reported for
five studies (Ensiyeh 2009; Smith 2002; Smith 2004; Vutyavanich
2001; Willetts 2003). Worsening of symptoms was reported in
two studies (Bsat 2003; Rosen 2003). Three studies reported on
maternal weight loss/gain, which we had not prespecified as a
maternal outcome (Jamigorn 2007; Keating 2002; Rosen 2003);
this could be viewed as being related to symptom control, but
is presented with the secondary outcomes in the results section.
In addition, seven studies described the side effects of treatment
such as headache, heartburn or sleepiness (Chittumma 2007;
Erez 1971; Knight 2001; McGuiness 1971; Pongrojpaw 2007;
Sripramote 2003; Willetts 2003).
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Our secondary outcomes included quality of life of women during
pregnancy, and economic costs (directly to women, productivity
costs, and costs to the healthcare system). Two studies (Smith
2002; Smith 2004) measured Quality of LIfe using the MOS 36
Short FormHealth Survey (SF36). One study (Knight 2001) used
the Hospital Anxiety and Depression Scale. No studies measured
economic costs.
See the Characteristics of included studies tables for more infor-
mation on participants, interventions and outcomes measured.
Studies awaiting further assessment and ongoing studies
Four studies are awaiting further assessment; in all four cases stud-
ies were reported in brief abstracts, and our initial attempts to
contact authors, or to identify subsequent publications have not
been successful (Adamczak 2007; Biswas 2006; Hsu 2003; Mamo
1995). If we identify further reports from these studies we will re-
assess eligibility.
Two studies are ongoing. One multicentre trial (Nguyen 2008)
examining the use of Diclectin (Debendox) for nausea and vom-
iting in pregnancy is planned to end in late 2009. We hope to in-
clude results from this study, if available, in updates of this review.
Another study (Wibowo 2009) is comparing the effectiveness of
different doses of vitamin B6 (“high” and “low” doses, which are
undefined in the trial record).
Excluded studies
After assessment of study eligibility we excluded 22 studies iden-
tified by the search strategy. The main reason we excluded stud-
ies was because they were not randomised trials, or they used a
crossover design. Six studies used quasi-randomised designs, for
example allocation according to day of the week, or alternate allo-
cation (Baum 1963; Can Gurkan 2008; Diggory 1962; Dundee
1988; Fitzgerald 1955; Winters 1961); such studies are at high
risk of bias, and were therefore not included in the review. In
three studies it was not clear to us that there was any sort of
random allocation to groups (Conklin 1958; Lask 1953; Steele
2001). Seven studies used a crossover design (Bayreuther 1994;
Cartwright 1951;DeAloysio 1992; Evans 1993;Hyde 1989; King
1955; Wheatley 1977); such designs are not usually appropriate
during pregnancy when symptoms may not be stable over time.
We excluded three studies as they focused on women with hyper-
emesis gravidarum, a group that we had decided to exclude from
the review (Heazell 2006; Higgins 2009; Kadan 2009). Two of
these studies are ongoing (Higgins 2009; Kadan 2009). We ex-
cluded one study because it was reported in a trial registry, and we
found no evidence that the study had taken place; we carried out
a search of databases to look for any publications from the study
without success (Luz 1987). One study did not focus on the relief
of nausea, but rather on hypocorticalism in pregnancy (Ferruti
1982); and finally, one trial record describes a study which looked
at pre-emptive treatment (before any symptoms appear) with a
combination of pyridoxine hydrochloride and doxylamine succi-
nate (Diclectin) in a subsequent pregnancy for women who had
experienced severe symptoms of nausea/vomiting of pregnancy (or
hyperemesis gravidarum) in a previous pregnancy (Koren 2006).
Risk of bias in included studies
Allocation
Sequence generation
In eight of the included studies the method used to generate
the randomisation sequence was not described or was not clear
(Erez 1971; Fan 1995; Geiger 1959; McGuiness 1971; Ozgoli
2009; Pongrojpaw 2007; Price 1964; Werntoft 2001). In the
study by Belluomini 1994 the trial was described as having a bal-
anced block design, but it was not clear how the sequence or-
der was generated or what the block size was. All the remain-
ing studies were assessed as having adequate methods to gener-
ate the randomisation sequence: four studies used external ran-
domisation services (Jamigorn 2007; Smith 2002; Smith 2004;
Willetts 2003), five studies used computer-generated sequences
(Bsat 2003; Keating 2002; Knight 2001; O’Brien 1996; Rosen
2003) (although the small block size in the Knight 2001 study
(four) may havemeant the sequence could be anticipated); and the
remaining seven studies reported the use of tables of random num-
bers (Chittumma 2007; Ensiyeh 2009; Puangsricharern 2008;
Sahakian 1991; Sripramote 2003; Vutyavanich 1995; Vutyavanich
2001).
Allocation concealment
In 12 studies the methods used to conceal the study group al-
location were not described or were not clear (Belluomini 1994;
Bsat 2003; Ensiyeh 2009; Erez 1971; Fan 1995; Newlinds 1964;
Norheim 2001; Ozgoli 2009; Pongrojpaw 2007; Puangsricharern
2008; Sahakian 1991; Werntoft 2001). In the remaining studies
we judged that themethodswere adequate; four studies used an ex-
ternal randomisation service (Jamigorn 2007; Smith 2002; Smith
2004; Willetts 2003); five used sealed opaque sequentially num-
bered envelopes (Chittumma 2007; Knight 2001; Rosen 2003;
Sripramote 2003; Vutyavanich 2001); one (O’Brien 1996) used
numbered sealed envelopes, without stating if they were opaque or
not; and in five placebo controlled trials, coded drug boxes or con-
tainers were used (Geiger 1959; Keating 2002; McGuiness 1971;
Price 1964; Vutyavanich 1995).
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Blinding
Most of the studies included in the reviewwere placebo controlled.
In three studies the routes of treatment administration (oral, in-
jection etc) were different and double/multiple placebo control
was not attempted (Bsat 2003; Chittumma 2007; Fan 1995). In
two studies, where there were more than two active intervention
arms, the type of treatment was blinded but the control condition
(no intervention) was not (O’Brien 1996; Werntoft 2001). In all
studies, all symptomatic outcomes were self-assessed by women,
whether recorded by women themselves or a researcher.
The success of blinding was not reported in most trials. Where
the treatment involved acupressure, acustimulation, or acupunc-
ture, blinding may not have been convincing to women or clin-
ical staff. In one acupuncture trial (Knight 2001), the author re-
ported that there was no attempt to blind clinical staff, but women
were described as being blind to group allocation. In five studies
(Chittumma 2007; Knight 2001; Norheim 2001; Smith 2002;
Smith 2004), the authors examined whether blinding was actu-
ally effective. It was reported in these studies that blinding may
not always have been effective. We will return to this issue in the
discussion.
Incomplete outcome data
The amount of missing outcome data in most of these studies was
generally low, with attrition levels below 10%; in these studies
most womenwere available to followup, although there weremiss-
ing data for some outcomes. There were higher rates of attrition in
the studies by Pongrojpaw 2007 (11%), Willetts 2003 (17.5%),
Rosen 2003 (18.6%), Knight 2001 (20%) and Newlinds 1964
(20%). In four studies attrition was greater than 20% (Sahakian
1991 (20.2%, attrition per group not stated); Smith 2002 (24%
by week four of a four-week study), Smith 2004 (29.3% by day
21) and Belluomini 1994 (33%). The reasons for attrition var-
ied and eight studies stated that women were lost to follow up
for reasons that may have related to study outcomes (e.g. because
they developed more severe symptoms, did not comply with tak-
ing study medication, or had adverse events) which may have put
these studies at particularly high risk of bias (Belluomini 1994;
Bsat 2003; Jamigorn 2007; Keating 2002; Knight 2001; Newlinds
1964; O’Brien 1996; Rosen 2003). In one study (Erez 1971),
there was no attrition at three weeks, but for the later follow-up
data on pregnancy outcome, there was high attrition (24%), as
these women had given birth elsewhere. The reasons for this were
not given, so it is possible that women were referred for high-risk
deliveries or other adverse events; again, there may be a high risk
of bias in this study. In one study (McGuiness 1971), the number
of women randomised was not clear, making it impossible for us
to assess attrition. In another study (Werntoft 2001), the approxi-
mate number of questionnaires (n = 80) given out was stated, and
the study stopped when 20 per group returned them, but it is not
known how many per group had been given out, and therefore,
attrition cannot be accurately measured. Intention-to-treat (ITT)
analysis was reported for two studies (Jamigorn 2007 (drop-outs
counted as treatment failures); Knight 2001), and Vutyavanich
2001 included the three placebo drop-out participants in the re-
sults, assuming relief equal to best improvement in the placebo
group.
Selective reporting
Although most of the studies provided some data on nausea, or
relief fromnausea, information on other outcomes was sparse. Not
all subscales were reported for instruments such as the Rhodes In-
dex (Belluomini 1994). Data from only selected time points were
presented in some studies (Belluomini 1994; Keating 2002). In
one study, results were presented using the number of assessments
of outcomes (280 assessments for 35 participants in the control
group and256 assessments for 32participants in treatment group),
rather than the number of participants (Ozgoli 2009). Statements
in the text about results were not always backed up with numerical
results (e.g. Belluomini 1994 (re results from days eight to 10);
Bsat 2003 (re drug use and compliance)).
As stated above (Included studies), few studies described side ef-
fects from treatment or adverse events for mothers or babies.
In six studies we had difficulty interpreting outcome data as they
were presented only, or largely, in graphical form (Bsat 2003;
Jamigorn 2007; Norheim 2001; O’Brien 1996; Rosen 2003;
Willetts 2003).
Some studies (Pongrojpaw 2007; Sahakian 1991; Smith 2002)
provided a large amount of outcomedata, for example,mean scores
on several dimensions of scales recorded over several days. Inter-
preting such data is not simple, and increases the risk of spurious
statistically significant findings.
Other potential sources of bias
Three studies reported drug company involvement (provision of
drugs and placebo, funding, or other sources of support) (Keating
2002; McGuiness 1971; Willetts 2003). One study stopped early;
in this trial it was stated that approximately 80 women were ran-
domised, but the study was ended when 20 women in each of
three groups had returned their data collection forms (Werntoft
2001). In the Price 1964 trial, some baseline imbalance between
study groups in terms of gestational age at recruitment was re-
ported, and in the Puangsricharern 2008 study there were dif-
ferences in baseline demographic characteristics, with the control
group participants having higher education and income levels than
the treatment group. In one study (Geiger 1959), two women
were included in both the treatment and control groups, as they
received medication on two separate occasions when they visited
the clinic during the study period. In several studies (for example,
Jamigorn 2007 and Rosen 2003), women were free to take other
medication which may have had a bearing on outcomes; without
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information on what other medication women were using, it is
difficult to interpret these data. In the Bsat 2003 study, women
in one of the intervention groups received vitamin B6 as well as
the main intervention (an anti-emetic). Therefore, it is possible
that the vitamin supplement had some independent or interaction
effect on outcomes.
Figure 1 and Figure 2 show the summary and graph of method-
ological quality, respectively. These highlight that, across studies,
there is a lack of clarity on many ’risk of bias’ criteria, particularly
in relation to sequence generation and allocation concealment, se-
lective reporting and other possible sources of bias.
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Figure 1. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Figure 2. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
Effects of interventions
Interventions for nausea and vomiting in early
pregnancy: 27 studies with 4041 women
Primary outcomes
The primary outcomes for this review were as follows.
1. Symptomatic relief (specifically a reduction or cessation in
nausea, retching and/or vomiting).
2. Adverse maternal and fetal/neonatal outcomes.
i) Adverse maternal outcomes included pregnancy
complications (antepartum haemorrhage, hypertension, pre-
eclampsia) .
ii) Adverse fetal/neonatal outcomes included fetal or
neonatal death, congenital abnormalities, low birthweight or
early preterm birth.
Symptomatic relief
P6 Acupressure versus placebo (four studies with 408
women)
Four studies compared P6 acupressure to placebo, and we have
included data from three of these in the data tables. None of these
studies showed evidence of a statistically significant effect for acu-
pressure. Results from one study (Norheim 2001) favoured P6
acupressure for improving (i.e. reducing) the intensity of symp-
toms, but the difference between groups was not statistically sig-
nificant (risk ratio (RR) 0.78, 95% confidence interval (CI) 0.44
to 1.39). After three days of treatment there was no strong evidence
that, compared with placebo, the treatment improved nausea in
the Werntoft 2001 trial (mean difference (MD) 0.10, 95% CI -
1.49 to 1.69). Using scores averaged over one to three days, results
from the Belluomini 1994 study did not show that acupressure
improved scores on the nausea and vomiting subscales or on the
total Rhodes Index score (for nausea MD 0.39, 95% CI -0.80
to 1.58, for vomiting MD 0.26, 95% CI -1.06 to 1.58, for total
Rhodes score MD 1.17, 95% CI -1.52 to 3.86).
One further study (O’Brien 1996) compared P6 acupressure and
placebo, but data from this study were not in a form that allowed
us to enter them into RevMan tables. The authors reported no
statistically significant differences between treatment and placebo
groups for symptom relief.
P6 Acupressure versus vitamin B6 (one study with 66
women)
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Jamigorn 2007 compared P6 acupressure with vitamin B6 and
results showed no statistically significant difference between the
two interventions for improvement of nausea on day three (data
obtained from authors) (MD 0.20, 95% CI -2.24 to 2.64). The
authors also report on the use of rescue medication (which may
be a proxy measure for lack of symptom relief ); results favoured
P6 acupressure (MD -2.2, 95% CI -3.98 to -0.42). Jamigorn
2007 also compared P6 acupressure and vitamin B6 in terms of
satisfaction with the intervention (which could be considered as a
proxy for its effectiveness); results suggest that women were more
satisfied with acupressure but evidence of a difference between
groups did not reach statistical significance (MD 0.40, 95% CI -
0.04 to 0.84).
Auricular acupressure versus placebo (one study with 91
women)
One study compared auricular acupressure (administered by par-
ticipants by pressing on magnetic balls taped to an acupressure
point on the ear) with placebo (no treatment) (Puangsricharern
2008). The authors report that they were using mean total Rhodes
Index score and total number of vomiting episodes from days four
to six to measure treatment effect. They subsequently concluded
that there were no significant differences between groups (though
average Rhodes scores across these days were not directly reported).
The treatment started on day three (for the acupressure group) and
the results for the total Rhodes score at day six (three days after
treatment started) appear to favour the treatment group, although
scores were lower in this group at baseline so results are difficult to
interpret (MD -3.60, 95% CI -6.62 to -0.58 Analysis 3.1). There
were no differences between groups for the number of anti-emetic
drugs used (MD - 0.10, 95% CI -0.37 to 0.17).
Acustimulation versus placebo (one study with 230 women)
Rosen 2003 compared low-level nerve stimulation therapy over the
volar aspect of the wrist at the P6 point with placebo. In this study,
nausea symptoms were recorded over three weeks, with weekly
assessments of changes from baseline. The author reported the
“time-averaged” change in the Rhodes Index total experience scale
over the entire three-week study period, and suggested that there
was more improvement over time in the active treatment group
(change score 6.48 (95% CI 5.31 to 7.66) versus 4.65 (95% CI
3.67 to 5.63) in the placebo group (data not shown in analysis ta-
bles). In this study, both groups experienced improved scores over
the evaluation period, and data (presented in graphical form in
the study report) were not simple to interpret. Results for women
in the Rosen 2003 study with mild to moderate symptoms were
described in an abstract by De Veciana 2001, and in another brief
abstract results were reported for those women with severe symp-
toms (Miller 2001). However, neither abstract provided usable
data for subgroup analysis.
Acupuncture versus placebo (two studies with 648 women)
One trial compared traditional acupuncture, P6 acupuncture,
sham acupuncture and no treatment (Smith 2002). The data ta-
bles show three comparisons: between both traditional and P6
acupuncture and sham acupuncture, and between traditional and
P6 acupuncture. None of the results show significant differences
(Analysis 5.1 to Analysis 7.3) for relief from nausea, dry retching
and vomiting. Knight 2001 also compared acupuncture to placebo
but the data were not in a form that allowed us to enter them in
RevMan 2008 tables; the authors used median scores because of
the skewness of the data. They report no statistically significant
differences between the control and intervention groups for symp-
tom relief.
Moxibustion versus Chinese drugs (one study with 302
women)
Fan 1995 reported that in a study comparing moxibustion with
Chinese drugs, symptoms for all women in both groups either
“improved” or were “cured”.
Ginger versus placebo (four studies with 283 women)
Ginger was compared with placebo in four studies (Keating 2002;
Ozgoli 2009; Vutyavanich 2001; Willetts 2003), although one
study didnot provide data on symptomatic relief in awaywhichwe
could use (Willetts 2003). In a small study (n=26) (Keating 2002),
results favoured ginger over placebo for improving nausea by day
nine (RR 0.29, 95%CI 0.10 to 0.82). Results also favoured ginger
for stopping vomiting at day six (RR 0.42, 95% CI 0.18 to 0.98).
In the study by Vutyavanich 2001 (n = 70), results suggested that
improvement innausea symptomswas greater in the placebo group
over four days of treatment (MD 1.20, 95% CI 0.22 to 2.18),
but when ITT analysis was carried out (to include three missing
patients in the placebo group counted as treatment failures), the
evidence of a difference between groups was no longer statistically
significant (MD 0.60 95% CI -0.51 to 1.71).
Ozgoli 2009 also compared ginger with placebo and presented the
results on nausea intensity using the total number of nausea-in-
tensity assessments per group (assessments were carried out twice
daily over four days for each participant, resulting in a total of 280
assessments for treatment group and 256 assessments for control
group). Apart from those results which are not easily interpreted,
and have not been included in our analysis, improvements in nau-
sea intensity are reported in percentages per group (from which
numbers have been calculated and analysed in this review). Data
on overall improvements appear to have been gathered during in-
terview (by an unblinded researcher) on day five, rather than by
comparing scores over time, but this is unclear. These results show
a statistical difference between groups, favouring the treatment
group (RR 1.48, 95% CI 1.07 to 2.04) on “nausea intensity im-
provement”. The authors also report a reduction in the incidence
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of vomiting following treatment of 50% in the intervention group
compared with 9% in the control group, although the original
data on post-treatment vomiting are not reported, and are not in-
cluded in our analysis tables.
Ginger versus vitamin B6 (four studies with 624 women)
Four trials compared ginger and vitamin B6 (Chittumma 2007;
Ensiyeh 2009; Smith 2004; Sripramote 2003).
In the two trials comparing ginger to vitamin B6 that had com-
parable outcomes reported (Chittumma 2007; Sripramote 2003),
no statistically significant difference was found between groups
(SMD -0.00, 95% CI -0.25 to 0.25, I² = 0%) for symptom scores
on day three. Results from the Chittumma 2007 study favoured
ginger compared with vitamin B6 using the Rhodes Index to mea-
sure symptom relief, while in the Sripramote 2003 trial results
favoured vitamin B6, using a 10 cm VAS to measure level of nau-
sea; but neither of these results was statistically significant. Post-
treatment number of vomiting episodes on day three was simi-
lar in the two intervention groups in the Sripramote 2003 trial
(MD 0.00, 95% CI -0.60 to 0.60). Ensiyeh 2009 and Smith 2004
present results on improvement in symptoms and pooled results
show no statistically significant difference between groups for the
number of women reporting no relief (RR 0.84, 95% CI 0.47 to
1.52 (random-effects)) although there was moderate heterogene-
ity for this outcome and results should be interpreted with caution
(heterogeneity: T2 = 0.11, I2 = 52%. P = 0.15).
Ginger versus Dimenhydrinate (one study with 170 women)
One study (Pongrojpaw 2007) compared ginger and dimenhydri-
nate, but the results for symptomatic relief were not easily inter-
preted and therefore, data have not been added to data tables in
RevMan 2008.
Vitamin B6 versus placebo (two studies with 416 women)
In two studies comparing vitamin B6 with placebo (Sahakian
1991; Vutyavanich 1995), results favoured vitamin B6 for reduc-
tion in nausea after three days (MD 0.92, 95% CI 0.40 to 1.44).
Comparing the number of patients vomiting post-treatment, there
was no strong evidence that vitamin B6 reduced vomiting (average
RR 0.76, 95% CI 0.35 to 1.66). As there was high heterogene-
ity for this outcome we used a random-effects model and results
should be interpreted with caution (heterogeneity: I² = 77%, T²
= 0.25, P = 0.04).
Anti-emetic medication versus placebo (six studies with 803
women)
There were six studies of anti-emetic medications. A range of anti-
emetics (Hydroxyzine, Debendox (Bendectin) Thiethylperazine
and Fluphenazine-Pyridoxine) were compared with placebos, and
in one study, three anti-emetic medications were compared.
One study (Erez 1971) compared Hydroxyzine to placebo, with
the results favouring Hydroxyzine for relief of nausea (RR 0.23
95% CI 0.15 to 0.36).
Bsat 2003 compared three drug regimens: Pyridoxine-metoclo-
promide, Prochlorperazine and Promethazine. Results were re-
ported in graphs and we have not entered estimated figures into
data tables. Approximately 65%, 38% and 40% of women in each
group, respectively, responded that they felt better on the third
day of treatment. The authors conclude that their results favour
Pyridoxine-metoclopromide over the other two regimens.
Two studies (Geiger 1959 and McGuiness 1971) compared
Debendox (Bendectin) with placebo, and results for nausea relief
favoured the intervention group. However there was high hetero-
geneity when results from these two studies were combined, and
the time point at which outcome data were collected was not clear
in the McGuiness 1971 study, and so in the analyses we have pro-
vided subtotals only. In the McGuiness 1971 study, while fewer
women in theDebendox group had no relief in symptoms, the dif-
ference between groups was not statistically significant (RR 0.65,
95% CI 0.36 to 1.17). In the Geiger 1959 study, only three of 52
women receiving Debendox reported no improvement in symp-
toms compared with 20/57 for controls.
Thiethylperazine was compared with placebo in one study and
women in the placebo group were less likely to experience symp-
tom relief (RR 0.49 95% CI 0.31 to 0.78) (Newlinds 1964). Fi-
nally, fluphenazine-pyridoxine seemed to improve symptoms com-
pared with placebo in one trial, but results did not reach statistical
significance (RR 0.52, 95% CI 0.27 to 1.01) (Price 1964); this
is an antipsychotic drug (from the piperazine class of phenoth-
iazines).
Adverse maternal and fetal/neonatal outcomes
Adverse maternal and fetal outcomes were reported for some stud-
ies across several comparisons.
Acupressure versus vitamin B6
Weight gain was reported by Jamigorn 2007 and results favoured
the acupressure group (MD 0.70, 95% CI 0.24 to 1.16), with
higher weight gain in this group.
Acupressure versus placebo
Norheim 2001 reported that 63% of participants in the acupres-
sure group and 90% in the placebo group reported problems (in-
cluding pain, numbness, soreness and hand-swelling) using the
wristband. Three women (two in the treatment group, one in the
placebo group) said they felt more sick during the study period.
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Acustimulation versus placebo
Rosen 2003 reported on weight gain, dehydration and ketonuria.
There was significantly more weight gain and less dehydration in
the treatment group (MD 1.70, 95% CI 0.23 to 3.17; RR 0.24,
95% CI 0.07 to 0.83 respectively) but there was no significant
difference for ketonuria at the end of the trial period (RR 0.48,
95% CI 0.15 to 1.55). The authors report that there was no sig-
nificant difference between groups on entry to the trial for ke-
tonuria, though those most likely to withdraw from the study had
ketonuria at entry (but at non-significant level).
GInger versus placebo
Vutyavanich 2001 reported on the rates of spontaneous abortion,
with no significant difference between groups (RR 0.36, 95% CI
0.04 to 3.33). Similarly, for delivery by caesarean section, there was
no difference between groups (RR 1.64, 95% CI 0.51 to 5.29).
The authors reported that there were no congenital abnormalities
in either group. As with the other studies reporting such fetal out-
comes, this study did not have sufficient power to show differences
between groups; we will return to this in the discussion.
Willetts 2003 compared fetal adverse outcomes (such as stillbirth,
neonatal death, preterm delivery, congenital abnormalities) with
expected numbers based on data at one hospital in Sydney. The
results were not clearly presented by randomisation group, but
were shown for the overall number who completed themain study,
with descriptive text about the number in the ginger group. The
authors concluded that those exposed to ginger did not appear to
be at greater risk of fetal abnormalities.
Also in a study of ginger versus placebo, Keating 2002 reported
weight change measured at the four week follow-up visit, but data
were not presented in a usable form; the authors commented that
most women in both groups maintained or gained weight.
Ginger versus vitamin B6
Smith 2004 reported on outcomes including spontaneous abor-
tion, stillbirth, heartburn, congenital abnormality, antepartum
haemorrhage/abruption or placenta praevia, pregnancy-induced
hypertension, pre-eclampsia and preterm birth. There were no
neonatal deaths in either group and no significant differences be-
tween the groups (Analysis 9.4 to Analysis 9.10). Similarly in
Ensiyeh 2009, no significant differences were found in the mater-
nal and fetal outcomes reported (spontaneous abortions, caesarean
delivery, congenital anomaly of the baby (Analysis 9.4, Analysis
9.6, Analysis 9.15). The authors report that “all were discharged
in good condition”, though elsewhere they say that data collection
and follow up took 12 weeks; women were recruited to the trial
at 17 weeks’ gestation or less, implying a longer follow-up time.
Chittumma 2007 reported on arrhythmia and headache, with
no evidence of a difference in effect between groups (Analysis
9.12; Analysis 9.11). Two studies (Chittumma 2007; Sripramote
2003) report results for heartburn, with no significant effect (RR
2.35, 95% CI 0.93 to 5.93, heterogeneity: I² = 3%, P = 0.31).
Chittumma 2007 reported on drowsiness, with neither ginger nor
vitamin B6 favoured (RR 0.65, 95% CI 0.27 to 1.56). Sripramote
2003 reported on sedation, with no strong evidence for either in-
tervention (RR 0.81, 95% CI 0.47 to 1.39).
Ginger versus dimenhydrinate
Pongrojpaw 2007 reported on the side effects of drowsiness and
heartburn.More people in the dimenhydrinate group experienced
drowsiness, whilemore in the ginger group experienced heartburn,
but evidence of differences between groups was not statistically
significant (drowsiness: RR 0.08, 95%CI 0.03 to 0.18; heartburn:
RR 1.44, 95% CI 0.65 to 3.20).
Antiemetic drugs
In the trials of anti-emetic drugs, fetal outcome was recorded only
by Erez 1971. In that study, of the 79 cases available for follow
up in the hydroxyzine group, there were four spontaneous abor-
tions (three in the first trimester and one in the second trimester)
and one perinatal death. In the 36 cases available for follow up
from the placebo group, there were two first trimester spontaneous
abortions (spontaneous abortions: RR 0.91, 95%CI 0.17 to 4.75;
perinatal mortality: RR 1.39, 95% CI 0.06 to 33.26). In the text,
the authors report that slight drowsiness was reported by 7% (n
= 7) of the treatment group, but no other adverse effects were re-
ported, and there were no hospitalisations in either group.
Bsat 2003 reported a non-significant difference in hospitalisa-
tion across the three groups receiving pyridoxine-metoclopramide,
prochlorperazine and promethazine. They comment that sub-
sequent pregnancy courses were similar and only one neonatal
anomaly was seen (a cardiac defect in the prochlorperazine group).
McGuiness 1971 stated that side effects were reported by 12 pa-
tients in the Debendox group (including drowsiness for three pa-
tients, feeling weak for two, tiredness for two) compared to six
adverse effects reported in the placebo group (including tiredness,
sleepiness, depression and constipation). Newlinds 1964 reported
that side effects occurred in 12 of the 93 patients who received thi-
ethylperazine and 10 of the 87 in the placebo group. These adverse
effects included drowsiness (four treatment, three placebo), aggra-
vation of nausea (two treatment, three placebo), “cerebral stimula-
tion”, described as mild in the text, and included restlessness (two
in treatment group, none in placebo). Price 1964 reported that
there were no side effects in the fluphenazine-pyridoxine group
and one patient in the placebo group reported drowsiness. Geiger
1959 reported that one patient in the Bendectin group reported
listlessness; no other adverse effects were reported.
Secondary outcomes
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The secondary outcomes for this review were:
1. quality of life (emotional, psychological and physical well-
being, women’s assessment of the pregnancy experience, women’s
coping with the pregnancy);
2. economic costs (direct financial costs to women,
productivity costs and/or health system costs).
Only three studies reported quality of life (and related) results
(Knight 2001; Smith 2002; Smith 2004).
Knight 2001 used the Hospital Anxiety and Depression Scale
(HADS) and reportedmedian scores for the intervention and con-
trol groups, but the data were not in a form that allowed us to enter
them in RevMan 2008 tables. The authors report that for both
anxiety and depression scores, there was no evidence for a group
effect or a group-time effect, but there was for a time effect (in
favour of acupuncture). However, both scores dropped over the
course of the study for both groups. The median rating of global
effectiveness was the same for both groups.
Smith 2002 and Smith 2004 used theMOS36 Short FormHealth
Survey. Smith 2002 reported the change in mean scores on the
SF36 Form (Quality of Life) for the four groups receiving tradi-
tional acupuncture, P6 acupuncture, sham acupuncture and no
treatment, respectively. They report eight sets of results for three
time points and highlight in the text that there was a group effect
on the social function andmental health SF36 domains, favouring
traditional acupuncture in both cases. Smith 2004 also reported
changes in mean scores across eight domains of the SF-36, with
a significant difference, favouring ginger, found only in two do-
mains: social function and physical role function.
No study reported economic data of any sort.
D I S C U S S I O N
Summary of main results
Nausea and vomiting in early pregnancy are common. Symptoms
are generally self-limiting, are not usually life threatening and, pro-
vided women do not have very severe vomiting, do not often lead
to serious complications.Nevertheless, early pregnancy nausea and
vomiting may be extremely distressing to women, andmay disrupt
their physical and social functioning. In this context, and in view
of concerns about the possible teratogenic effects of pharmacolog-
ical agents, non-pharmacological approaches to symptom control
have become increasingly popular and have been recommended
in clinical practice guidelines (NICE 2008).
In this review we found little strong or consistent evidence that
non-pharmacological therapies are effective in reducing symp-
toms. Evidence regarding the effectiveness of P6 acupressure (in-
cluding acustimulation at this point) was limited. There was some
evidence of the effectiveness of auricular acupressure, though fur-
ther larger studies are required to confirm this. Acupuncture (P6
or traditional) showed no significant benefit to women with nau-
sea and vomiting in early pregnancy. The use of preparations con-
taining ginger may be helpful to women, but in this review the
evidence of effectiveness was limited, and not consistent.
We also found only limited evidence from trials to support the use
of pharmacological agents including vitamin B6, antihistamines,
and other anti-emetic drugs to relieve mild or moderate nausea
and vomiting (a related Cochrane review is examining their use
in women with more severe symptoms). There were no studies of
dietary or other lifestyle interventions identified.
Overall completeness and applicability of
evidence
We attempted to be as inclusive as possible in the search strategy
and have included studies reported in languages other than En-
glish. Nevertheless, the literature included in the review was pre-
dominantly reported in European and North American journals
and this may have introduced some bias and limited the applica-
bility of results.
Interpreting the findings of the studies included in the review was
not simple. Some of the studies were more than 50 years old and
during the time period covered by this research, the attitudes of
women and clinical staff towards symptoms and towards symp-
tom relief may have changed. Most of the studies examining non-
pharmacological approaches have been published more recently,
yet there is very little conclusive evidence on the efficacy of com-
plementary or alternative therapies.
The main focus of the review was on the effectiveness of interven-
tions to relieve symptoms. However, our prespecified outcomes
also included the impact of interventions on the well-being of
mothers and babies. Although there may be a perception that
complementary and alternative approaches are not ’invasive’, their
safety has not been adequately evaluated. Few studies reported
pregnancy outcomes, adverse effects from treatments, or adverse
events. It may not be safe to assume that because negative out-
comes were not reported that they did not occur. In those studies
(mainly those focusing on pharmacological interventions) that did
report data on side effects and adverse events, none had the sta-
tistical power to provide convincing evidence regarding relatively
rare adverse outcomes.
The studies reviewed here contained very little information on
the psychological, social or economic impact of nausea on preg-
nant women. The scales used tended to focus on the experience
of symptoms; but very little data were presented on other aspects
of quality of life such as the impact of nausea on family and social
functioning, or on relationships. Many women experience symp-
toms whilst attempting to care for young children or whilst at-
tending work; none of the studies reported on outcomes relating
to the impact of interventions on the ability to perform work, on
sickness absence from work, or on the economic impact of symp-
toms.
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Some of the interventions examined in the review, such as ginger
or acupressure wrist bands, may be transferable to clinical contexts
other than those in which theywere tested as theymay be relatively
low cost (although studies did not provide informationon this) and
acceptable to women and staff. Other interventions may require
special equipment not generally available in antenatal care settings
(e.g. acustimulation or acupuncture) and staff may need particular
skills and training; even if these interventions had been proven
effective, they may not be easily transferable between care settings.
Quality of the evidence
We were unable to pool findings from studies for most review
outcomes due to heterogeneity in study participants (e.g. stage of
pregnancy and severity of symptoms), interventions (and co-in-
terventions), comparison groups, and outcomes measured or re-
ported. For this reason, most of the results were derived from sin-
gle studies with findings that have not been replicated elsewhere.
Where results from more than one study were pooled, inconsis-
tencies in findings between studies was reflected in high levels of
statistical heterogeneity for some outcomes; we have indicated in
the results section those outcomes affected by high heterogeneity
and advise caution in interpreting those results.
The methodological quality of the included studies was mixed.
Some studies had high rates of attrition, poor allocation conceal-
ment and other methodological problems which put them at high
risk of bias. Lack of effective blinding may also have introduced
bias; although many of the included studies were described as be-
ing double blind or keeping women blind to group allocation,
we had concerns about the effectiveness of blinding. Sham acu-
pressure, acupuncture or acustimulation may not be convincing
to women. Some of the trials which investigated the effectiveness
of blinding provided some evidence that women may have had
some idea of group allocation (Chittumma 2007; Knight 2001;
Norheim 2001; Smith 2002; Smith 2004). The lack of blinding
or unconvincing blinding may be particularly relevant where the
main outcome is women’s subjective, self-reported symptoms. We
had intended to carry out sensitivity analysis whereby we would
exclude from the analyses those studies at high risk of bias to see
what impact this would have on findings; however, we did not do
this because we were unable to pool data for most interventions
and outcomes, and results were derived from single trials.
Lack of clear information on how studies were conducted and
in reporting results means that some findings may be difficult
to interpret. Few of the studies provided clear information on
whether or notwomenwere using other over-the-counter remedies
or prescribed medications to control symptoms. This informa-
tion would have been very helpful in understanding results. One
study reported the use of “rescue” medication (Jamigorn 2007). In
other studies the treatment effect may have been underestimated
if women in control groups were more likely than those in inter-
vention groups to use other treatments.
The effectiveness of vitamin B6 was difficult to interpret. In some
studies, vitamin B6 was the active intervention, in others it was
the control condition, and in at least one study it was given in
addition to one of the interventions (Bsat 2003); in this study it
was not clear whether the results obtained for the anti-emetic plus
B6 group were attributable to the anti-emetic alone, vitamin B6
alone or both acting together.
Theway inwhich outcomesweremeasured and reported in studies
varied considerably. Some studies used the validated instruments
described under Primary outcomes. Other studies used ordinal
data such as three- or five-point scales. In these cases, in order to
include data in the analysis tables, we converted the data into bi-
nary form by choosing cut-off points. We attempted to be consis-
tent in choice of cut off, opting for no relief versus improvement
in symptoms, but we acknowledge that the choice may have im-
pacted the results. There was also variation in the way continuous
data were collected, with some studies using visual analogue scales
or validated scales. Eight studies in the review used the Rhodes
Index. This was originally created tomeasure the nausea and vom-
iting symptoms of chemotherapy (Rhodes 1984), and has been
validated for use in studying these symptoms in pregnancy (Zhou
2001). However, the use of Rhodes Index of Nausea, Vomiting
and Retching, for example, was not consistent in studies; some
trials used shortened forms or did not collect or report data on all
subscales. Further, as wementioned earlier, in some trials datawere
collected repeatedly and a great deal of (not always consistent) data
were presented. In this review we have tried to present findings for
a time point approximately three days after the start of treatment,
but this was not always possible. The lack of consistency in the
way outcome data were measured and reported should be kept in
mind when interpreting results.
The use of pregnancy-specific nausea and vomiting measure-
ment instruments in future studies may facilitate better outcome
measurement. As described in Primary outcomes, the Pregnancy
Unique Quantification of Emesis (and nausea) (PUQE) has been
has been developed by clinician-researchers at theCanadianMoth-
erisk Program. This is a three-item (plus a global question) instru-
ment. The clinician-researchers had been using the Rhodes Index
and stated that they found it to be detailed but cumbersome and
time-consuming (Koren 2002b). They also noted the strong cor-
relations between the severity of a physical symptom and the stress
caused by that symptom. Also nausea was measured twice (dura-
tion and number of bouts (frequency) of nausea). They also felt
that, based on their experience, frequency of nausea was more dif-
ficult for women to define. The PUQE has been validated against
four independent criteria (Koren 2005) and with an established
Quality of LIfe instrument (Lacasse 2008) and it has been used in
studies that were not included in this review (for example Koren
2006).Other pregnancy-specific instruments have been developed
(Magee 2002b; Swallow 2002) but these have not been used in
published randomised controlled trials identified within this re-
view).
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Potential biases in the review process
We acknowledge that there was the potential for bias at all stages in
the reviewing process.We attempted tominimise bias in a number
ofways; for example, two review authors independently carried out
data extraction and assessed risk of bias. However, we acknowledge
that such assessments involve subjective judgments, and another
review team may not have agreed with all of our decisions. A
further possible source of bias (discussed above) was the choice of
time points for symptom assessment and the cut off points chosen
to convert ordinal into binary data for entry into RevMan 2008.
Again, we attempted to minimise bias by discussing such issues
and attempting to be consistent across studies and outcomes.
Agreements and disagreements with other
studies or reviews
Current clinical practice guidelines suggest that acupressure and
ginger may be useful in the relief of symptoms of nausea and
vomiting (NICE 2008). Our results suggest that the evidence un-
derpinning such recommendations is inconsistent and relatively
weak.
There are several other non-Cochrane reviews and overviews of
interventions for nausea and vomiting in pregnancy in the litera-
ture (Aikins Murphy 1998; Bryer 2005; Davis 2004; Jewell 2003;
Kousen 1993;Magee 2002a; Magee 2006;McParlin 2008; Niebyl
2002; Quinlan 2003; Wilkinson 2000). These reviews present
partial evidence to back up their conclusions. Bryer 2005 reviews
the same three studies of ginger included in this review (Keating
2002; Smith 2004; Vutyavanich 2001), and comments on the va-
riety of doses and preparations used and the lack of safety report-
ing. Nonetheless, drawing on an observational study of teratogeny,
Bryer 2005 concludes that “ginger is a safe and effective treatment
option for nausea and comparable with vitamin B6 in effective-
ness”. Our review found limited and inconsistent evidence of such
effectiveness. Davis 2004 proposes “an evidence based review” and
describes briefly the findings of some trials of both pharmaceu-
tical and non-pharmaceutical treatments, but does not comment
on the quality of studies and concludes that treatment has been
“poorly refined”.Magee 2002a offers an “evidence-based approach
of safety and effectiveness” of pharmacological therapies, and re-
produces a forest plot of various treatments from a previous review
(Mazzotta 2000). The authors conclude that evidence from con-
trolled trials has shown that Bendectin/Diclectin, antihistamine
blockers and phenothiazines as a group are safe and effective for
treatment. The current review would not support that simplistic
conclusion, based on the quality and consistency of evidence. A
more recent review (Magee 2006) does comment on the quality
of the trials reviewed and the lack of consistent outcome measure-
ment, as was also found in the current review. In a more recent
review, McParlin 2008 suggests that “ginger and acupressure are
two alternative therapies that have themost promising results from
clinical trials”, citing one clinical trial, one set of practice guide-
lines, one observational study on safety, and the previousCochrane
review on this topic (Jewell 2003a). However, Jewell 2003a had
concluded more cautiously that the single trial of ginger was en-
couraging, though its active ingredient is not known and that the
evidence on acupressure was mixed.
Some reviews include crossover studies, which is problematic as
symptoms generally improve over time. For example, Ernst 2000
includes one trial which studied ginger for nausea and vomiting
across different groups (postoperative sickness, seasickness, etc).
The included trial was a crossover study with 30 patients; nonethe-
less these study results are pooled with two other studies and found
to collectively favour ginger over placebo.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Women will continue to seek treatments for the often distressing
symptoms of nausea and vomiting in pregnancy. They may take
over-the-counter and complementary therapies, based on anecdo-
tal or peer advice. There are many sources of advice for women
on the Internet, including peer fora. Wilkinson 2000 found a lack
of consensus about safety of herbal treatments (including ginger)
for nausea and vomiting in pregnancy in 300 non-medical sources
identified in a literature review. This highlights the necessity of
health professionals providing clear guidance to women, based on
systematically reviewed evidence. On the basis of this review, high-
quality consistent evidence is lacking to support the accuracy or
appropriateness of that advice. Current guidelines and other re-
views often offer incomplete evidence, without comment on the
quality of evidence. Health professionals’ decisions about treat-
ments should take account of the lack of clear and consistent evi-
dence found in this review and acknowledge that it is not possible
at present to identify, with confidence, safe and effective interven-
tions for nausea and vomiting in early pregnancy.
Implications for research
The difficulties in interpreting the results of the studies included
in this review highlight the need for specific and clearly justified
outcomes in research on interventions for nausea and vomiting in
pregnancy. The range of instruments used to measure these symp-
toms (including those not developed for this patient group) also
suggest the need for a consistent and appropriate approach tomea-
surement, which may be addressed by the PUQE scale described
above. There is also a need to systematically measure quality of
life and adverse maternal and fetal and neonatal outcomes, to en-
sure that studies are of most usefulness to health professionals and
women seeking safe and effective treatments. We did not iden-
tify any studies of dietary or behavioural interventions. Dietary
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and behavioural strategies (eating low fat, small, frequent meals)
were often recommended to all participants (in both treatment
and placebo groups) within the studies in this review. Only one
study (Ozgoli 2009) measured adherence to dietary advice. The
effectiveness of dietary and other behavioural strategies also needs
to be evaluated in good quality trials.
A C K N OW L E D G E M E N T S
As part of the pre-publication editorial process, this review has
been commented on by four peers (an editor and three referees
who are external to the editorial team), a member of the Pregnancy
and Childbirth Group’s international panel of consumers and the
Group’s Statistical Adviser.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Belluomini 1994
Methods A randomised blinded study.
Participants 90 pregnant women, with gestation of 12 weeks or less by the completion of the study.
Exclusion criteria were diagnosed hyperemesis gravidarum, diseases that cause nausea
and emesis, and current use of anti-emetic medication
Interventions Treatment group received acupressure using an acupressure point (Nei Guan PC-6);
placebo point (on palmar surface of the hand, proximal to the head of the fifthmetacarpal
joint) used for the sham control group. Applied for 10 minutes 4 times per day
Outcomes Nausea and vomiting were measured using the Rhodes Index of Nausea and Vomiting
Form-2 (scale range of 0-32, 3 subscales: nausea (duration, frequency and distress),
vomiting (amount, frequency and distress) and retching (frequency and distress)
Outcomes were measured each evening for 10 consecutive days; data from the first 3
days were used as pre-treatment data; data from days 5-7 were used to measure treatment
effect
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Women were assigned by a randomised block design to
P6 acupressure or sham acupressure group.How this was
done is not described. Probably adequate, though size of
blocks not stated
Allocation concealment? Unclear Not described.
Blinding?
Change in grade of nausea or vomiting at
second visit compared to first
Yes Subjects and their referring practitioners were blind to
the group assignment (though this presupposes a lack of
knowledge of acupressure). Subjects self-reported out-
comes
Incomplete outcome data addressed?
Change in grade of nausea or vomiting at
second visit compared to first
Yes 30 of 90 participants did not complete the study (16
treatment and 14 control). Failure to return forms, very
incomplete forms or loss to follow up explained attri-
tion of 13 treatment and 12 control participants. The
remaining attrition (3 treatment and 2 control) was ex-
plained as prescribing anti-emetics, abdominal surgery
and voluntary dropout
Though this high attrition rate might introduce bias, it
is similar between groups
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Belluomini 1994 (Continued)
Free of selective reporting? No Retching subscale results not reported. Subscale results
for nausea and vomiting presented averaged for days 1-
3 and 5-7; data from days 8, 9, 10 were not presented; it
was reported in text that data from these days “demon-
strated no significant differences between the treatment
and placebo groups because nausea and vomiting had
improved over time” (average gestation 8.5 weeks +/- 1.
4 weeks)
Free of other bias? Yes Internal reliability of Rhodes Index reported for day 2
of pre-treatment (r = 0.88); not explained why this day
was chosen. Unlikely to introduce bias
Bsat 2003
Methods Prospective randomised comparison of 3 drug regimens.
Participants 169 women with singleton pregnancies in first trimester presenting to their obstetrical
provider with nausea and/or vomiting
Interventions 3 “commonly prescribed pharmaceutical regimens in the outpatient management of
nausea and vomiting in pregnancy”, to “mirror local practices”
Group A: 50 mg intramuscular injection of pyridoxine, with metoclopramide 10 mg
orally every 6 hours as needed
Group B: prochlorperazine as needed 25 mg rectal suppositories every 12 hours or 10
mg tablets orally every 6 hours as needed
Group C: promethazine 25 mg orally every 6 hours as needed.
Outcomes Change in symptoms: scores 1-5 on a scale which comprised: much worse, worse, same,
better, much better; recorded by participants on third day of treatment. Responses then
divided into 2 subgroups:-those who answered 1-3 (same-worse) and those who answered
4-5 (better)
Women also recorded the number of emesis episodes the day before and on the third day
of treatment; dry heaves (retching) were counted as nausea, but not vomiting episodes
Worsening of symptoms was evaluated and patient admission for hydration or inpatient
management was considered on an individual basis
Hospitalisation for the specific management of nausea or vomiting was noted
Patients also recorded their “medication compliance”.
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Patients were divided into 3 groups based
on a computer-generated randomisation
27Interventions for nausea and vomiting in early pregnancy (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bsat 2003 (Continued)
Allocation concealment? Unclear Not described.
Blinding?
Change in grade of nausea or vomiting at
second visit compared to first
No Not blinded. The authors raise the possi-
bility of the “placebo effect” of the intra-
muscular route. The authors conclude that
it would have been ideal to randomise the
patients in a double blind fashion and pos-
sibly to establish a placebo group
Incomplete outcome data addressed?
Change in grade of nausea or vomiting at
second visit compared to first
Yes 12 patients lost to follow up (3, 5 and 4
from groups A, B and C respectively). 1
patient from Group A withdrew from the
study with side effects (acute dystonic re-
actions, thought to be secondary to meto-
clopramide)
Free of selective reporting? No Results for “subjective response” presented
only in graphical format; not usable
Emesis frequency only reported.
States that “drug usage and compliance was
comparable between all three groups”, but
no description of amount of each drug used
(most were on an “as required” basis)
Free of other bias? No 2 drugs were given to Group A; this treat-
ment was found to be most effective; it is
not possible to identify whether 1 or both
agents were effective. The authors note that
combining 2 agents that may also both
work independently may raise questions of
fairness - this was done tomirror local prac-
tices
Unclear who and where drugs were admin-
istered (e.g. IM injections on an “as re-
quired” basis). Study was done in out-pa-
tient setting
Chittumma 2007
Methods Randomised double-blind controlled trial.
Participants 126 pregnant women at 16 weeks’ gestation or less who had nausea and vomiting,
required anti-emetics, had no medical conditions, and were not hospitalised
Interventions Treatment group: 2, 325 mg capsules of ginger or placebo group: 2, 12.5 mg identical
capsules
Capsules taken 3 times daily before meals for 4 days.
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Chittumma 2007 (Continued)
Outcomes Primary outcome: change of nausea vomiting scores (mean of post-treatment minus
baseline scores). Symptoms recorded at baseline and each day during treatment
The 3 physical symptoms of Rhodes’s score were measured (episodes of nausea, duration
of nausea and number of vomits); range lowest score of 3 to maximum of 15
Secondary outcomes measured: occurrence of side effects such as heartburn, arrhythmia,
headache and sedation
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Women were randomly allocated. The ran-
domisation of patients was done using a ta-
ble of random numbers with blocks of 4 to
receive ginger or vitamin B6. When using
blocks of 4, it may be possible to predict
sequence
Allocation concealment? Yes The treatment code was concealed by plac-
ing the patient’s assignments in sequence in
sealed opaque envelopes that were drawn
in ascending consecutive order
Blinding?
Change in grade of nausea or vomiting at
second visit compared to first
Yes The codes were kept strictly confidential
for blinding the physician and subjects and
were broken at the endof the study.Women
self-reported outcomes
4 cases in the ginger group identified what
they were taking, none in the B6 group did
Incomplete outcome data addressed?
Change in grade of nausea or vomiting at
second visit compared to first
Yes 2 cases in the ginger group and 1 case in the
vitamin B6 group were lost to follow up
Free of selective reporting? Yes All outcomes reported.
Free of other bias? Unclear 1 person in the ginger group and 4 in the
B6 group took other medications (com-
mon cold, headache); 3 of the ginger group
and 4 of the B6 group took other ginger
products during the trial. At the end of the
trial, the use of other antiemetics was re-
ported by 7 of 12 patients (5.7%); unclear
what this means
The authors chose a study period of 4 days
because previous studies showed that the ef-
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Chittumma 2007 (Continued)
fect of ginger was evident within a few days
of treatment and too long a period would
result in a higher rate of subject noncom-
pliance and loss to follow up
Ensiyeh 2009
Methods Double-blind randomised controlled trial.
Participants Pregnant women with nausea, with or without vomiting, who first attended the antenatal
clinic at or before 17 weeks’ gestation. Women were excluded if they had other diseases
that might cause nausea and vomiting, had mental health problems, had taken tablets
in the previous week that might have aggravated nausea or vomiting symptoms, refused
to participate or were unable to return 1 week later for follow up
During the study, 80 women were eligible and 70 agreed to participate, 35 randomised
to each group
Interventions Ginger 1 g/day or vitamin B6 40 mg/day for 4 days (for both groups: 2 capsules daily,
after breakfast and dinner)
Outcomes Severity of nausea using a VAS, number of episodes of vomiting recorded, 3 times daily
during treatment for 4 days (average daily scores and mean nausea score calculated over
the 4 days of treatment). At 7 day follow up treatment response was assessed using a 5-
point Likert scale (much worse, worse, same, better, much better). Median change in
severity of nausea and number of vomiting episodes compared by group
Secondary outcomes also measured were: side effects and adverse effects on pregnancy
outcomes such as abortion, preterm birth, congenital anomaly, perinatal death and mode
of birth
Compliance was assessed by pill count and by asking women if they took the drugs
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes 35 women were randomised to the ginger
group and 35 to the vitamin B6 group, us-
ing a table of random numbers
Allocation concealment? Unclear No details given.
Blinding?
Change in grade of nausea or vomiting at
second visit compared to first
Yes Double-blind; women self-reported out-
comes.
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Ensiyeh 2009 (Continued)
Incomplete outcome data addressed?
Change in grade of nausea or vomiting at
second visit compared to first
Yes 1 woman randomised to vitamin B6 group
did not return to the clinic, so she was ex-
cluded from the study. Results presented
by intention to treat, after excluding the 1
woman
Free of selective reporting? Unclear Only changes in scores and number of
vomiting episodes presented, as well as fre-
quency of improvement in symptoms (by
category much worse to much better)
The authors stated that data collection and
follow up took 12 weeks; also stated that
pregnancy outcomes including preterm
birth, perinatal death, congenital anomaly,
mode of delivery were assessed, which
could not have been concluded within 12
weeks. Median changes in scores presented
only
Compliance/adherence to treatment is not
recorded.
Free of other bias? Yes Power analysis was said to be used to de-
termine the sample size, resulting in 31 per
group to achieve a power of 0.80 with an
alpha of 0.05; however effect size (presum-
ably for primary outcome) needed for the
calculation is not stated. Not likely to in-
troduce bias
Erez 1971
Methods Double blind study/evaluation.
Participants 150 pregnant women in the first 2 months of pregnancy, reporting recurrent nausea and
had vomited at least 3 times per week over the previous 2 weeks
Interventions Hydroxyzine Hydrochloride 25 mg capsules twice daily orally (morning and 2 pm) or
identical capsules of placebo for 3 weeks
Outcomes Effectiveness of the medication graded subjectively by the patient as follows: complete
relief, partial relief, no relief. Evaluation of effectiveness of drug and side effects was made
3 weeks after starting the medication
Side effects were evaluated (not stated how, by whom).
“Fetal wastage” and fetal anomalies checked.
Notes Initially no attempt was made to eliminate causes of recurrent vomiting other than
pregnancy
Comments that spontaneous remission or psychological factors may have played a role
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Erez 1971 (Continued)
and this was evident from the fact that 22% of the placebo group had some response
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear By random selection from the available preparations,
100 patients received Hydroxyzine and 50 patients
received the placebo
Allocation concealment? Unclear Not described.
Blinding?
Change in grade of nausea or vomiting at
second visit compared to first
Yes Neither the physicians involved not the patient recip-
ients knew which was the active drug and which the
placebo
Incomplete outcome data addressed?
Change in grade of nausea or vomiting at
second visit compared to first
Yes No missing data for follow up at 3 weeks (primary
outcome of symptom relief ); obstetrical outcome re-
ported for 115 (of 150); 21 of treatment group and
14 of control group could not be evaluated as they
delivered elsewhere
Free of selective reporting? Yes All outcomes reported.
Free of other bias? Unclear Blind evaluation of drug efficacy and any side effects
was made 3 weeks after the institution of the medica-
tion
There was a 2:1 ratio of treatment: control partici-
pants.
Fan 1995
Methods Randomised comparison/observation.
Participants 302 patients with pregnant vomiting, with menstruation suspended for more than 2
months (maximum not stated)
Interventions Patients were treated according to differentiation of symptoms and signs and types of
syndromes (1. deficiency of both the spleen and the stomach, 2. incoordination between
the liver and the stomach)
2 treatment groups:
Moxibustion group (specified points).
Chinese drug group (specified herbs).
Outcomes Criteria for evaluating the therapeutic effect: cured, improved, ineffective. Not described
who measured these. “Cure” defined as disappearance of symptoms after treatment for
1 week, but outcome measurement time-point(s) not specified
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Fan 1995 (Continued)
Notes Gestation unclear; more than 8 weeks since last menstrual period
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Patients were randomly divided into 2 groups;
no further details
Allocation concealment? Unclear No detail.
Blinding?
Change in grade of nausea or vomiting at
second visit compared to first
No Not attempted; different modes of treatment.
Incomplete outcome data addressed?
Change in grade of nausea or vomiting at
second visit compared to first
Yes All 151 per group reported on (total of 302).
Free of selective reporting? Yes Reported as % cured/improved. States that all
had improvement or cure
Free of other bias? Unclear Not stated who recorded outcome.
Concluding statement: “the therapeutic effect
of moxibustion is superior to that of Chinese
drug therapy. It is also simple and easy to be
performed, and it an ideal therapy”
Unclear about study design: first paragraph
states: “In the past several years, the author has
cooperated with some gynaecologists from this
and other hospitals to treat pregnant vomiting
with moxibustion therapy and achieved signif-
icant therapeutic effect. It is introduced as fol-
lows. General data. 302 and two [sic] patients
with pregnancy vomiting were randomly di-
vided into two groups, 151 cases in each group”
Geiger 1959
Methods Within a series of studies; a double-blind comparative experiment, a controlled double-
blind study
Participants 100 ward (not explained) and private patients.
Interventions Bendectin (10 mg each of Bentyl, Decapryn and Pyridoxine), 2 tablets nightly, an addi-
tional tablet in the morning as required
Placebo (not described).
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Geiger 1959 (Continued)
Outcomes Relief from nausea and vomiting: complete, partial or no relief
No description of how or when outcomes were measured.
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No description about randomisation.
Allocation concealment? Unclear No description about allocation conceal-
ment; tablets were in envelopes with an
identification number
Blinding?
Change in grade of nausea or vomiting at
second visit compared to first
Yes Neither the physician nor the patient was
aware of the identity of the tablet adminis-
tered
Incomplete outcome data addressed?
Change in grade of nausea or vomiting at
second visit compared to first
Yes 1 patient in treatment group receivedmed-
ication for 1 day, otherwise all patients’ out-
comes reported in results
Free of selective reporting? Yes Outcomes reported.
Free of other bias? Unclear 2 patients were included in both the treat-
ment and control groups as they received
medication on 2 separate occasions during
the study
Not stated how or when outcomes were
recorded.
Jamigorn 2007
Methods A single blind randomised study.
Participants 66 pregnant women with mild to moderate nausea and vomiting between 6 and 12
weeks’ gestation, in the outpatient setting
Interventions The patients in the acupressure group were advised to apply Sea-Bands on P6 point and
identical looking tablets were used as placebo in the same regimen as vitamin B6. Those
in vitamin B6 group were advised to apply Sea-Bands on the dummy point and 50 mg
tablets of vitamin B6 were prescribed every 12 hours for 5 days
Outcomes Primary outcome: self-recorded nausea and vomiting according to Rhodes Index of
Nausea andVomiting form2 (8 item, 5-point LIkert-type instrument).Women evaluated
their symptoms twice daily for 7 days
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Jamigorn 2007 (Continued)
Secondary outcomes: weight gain and medication use- use of the rescue drug (oral
dimenhydrinate 50 mg every 6 hours when required)
Notes The authors state that the Rhodes Index was “translated into Thai and tested for validity
and reliability by experts” but provide no other details on this
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Randomisation was done into 2 groups (acupressure
and vitamin B6 groups) by an independent remote
researcher who had no prior knowledge of the pa-
tients by using a block of 4 technique
Allocation concealment? Yes Sequential sealed envelopes picked by independent,
remote researcher
Blinding?
Change in grade of nausea or vomiting at
second visit compared to first
Yes “A single blind randomised study.”
A possible concern is whether since the study was
conducted in Thailand, participants might have
known where the P6 point was and therefore, would
have known when they were using ‘placebo’ acupres-
sure on the point that was not P6
Incomplete outcome data addressed?
Change in grade of nausea or vomiting at
second visit compared to first
Yes 6 patients did not complete the study (3 in each
group). The attrition of the 6 people was explained
as follows: “one patient from the withdrawal [sic]
group was lost to follow-up”, 1 had irritation from
the acupressure band, 2 patients lost their acupres-
sure devices, 2 patients had incomplete forms
ITT analysis was performed, counting all with-
drawals as treatment failures
Free of selective reporting? Unclear All outcomes reported but change in Rhodes score
only presented graphically; results for weight change
and rescue drug use presented fully
Free of other bias? Unclear The initial Rhodes Index score in the B6 group was
higher than acupressure group; stated to be not sig-
nificant, sample size 33 per group
The authors acknowledge that it is possible that the
rescue drug provided a large reduction of the symp-
toms but that it was not possible to exclude it for
ethical reasons. They state that the use of the rescue
drug did not differ by group (although they also re-
port 0.6+/-1.6 tablets vs 2.8 +/-4.7 tablets P > 0.05
in acupressure and vitamin B6 groups respectively)
They also state that the improvement of nausea and
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Jamigorn 2007 (Continued)
vomiting in the present study may be spontaneous
due to a placebo effect, the additional medications
used, or either of the treatments
Keating 2002
Methods Double blind placebo-controlled randomised clinical trial.
Participants Pregnant women in first trimester attending obstetric visit. 26 women were enrolled with
14 patients in the intervention group and 12 in the placebo group
Interventions Intervention group: tablespoon of syrup 250 mg ginger, honey and water
Placebo: water, honey, lemon oil.
1 tablespoon mixed in 4-8 ounces of cold water 4 times/day.
Outcomes Each subject kept a daily diary for first 2 weeks to record the number of syrup drinks
ingested and the degree of nausea and vomiting
Degree of nausea and vomiting “A numerical scale of 1 through 10 was used to quantify
the level of nausea, number of vomiting episodes and the patient’s perspective of her
daily functioning related to her symptoms”. No information about the scale
Outcomes reported:
point improvement on the nausea scale;
number of vomiting episodes;
maintenance/gain in weight.
Notes A statistical analysis was not applied to the results because of the small numbers
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Subjects were randomised to the placebo
or the study group by computer-generated
numbers matching the numbers on identi-
cal-appearing bottles of ginger or placebo
syrup
Allocation concealment? Unclear Nothing stated about allocation conceal-
ment.
Blinding?
Change in grade of nausea or vomiting at
second visit compared to first
Yes Described as “double blind”.
Participants: 1 woman withdrew - did not
like the taste - “no other patient indicated
that she could distinguish the taste of gin-
ger”
No further information about blinding
of study personnel “double-blinded”; out-
comes self-reported by participants
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Keating 2002 (Continued)
Incomplete outcome data addressed?
Change in grade of nausea or vomiting at
second visit compared to first
Yes Attrition from the placebo group - 1
woman did not take the study drink as
her nausea resolved, 2 women stopped the
study on days 7 and 11 because of no im-
provement and they were prescribed anti-
emetics
In the ginger group, 1 woman stopped the
study at day 5 as she could not tolerate the
taste of the drink; another woman stopped
the study on day 10 when her symptoms
resolved
Results are reported for days 6, 9, 14, for
groups with varying sizes, linked with this
attrition
Free of selective reporting? No Reported 4 point, 2 point improvement in
nausea; reported vomiting on day 6was not
pre-specified and seems arbitrary
Patient’s perspective on her daily function-
ing - not reported
Weight gain/loss reported in results - not
specified as an outcome
Free of other bias? Unclear The ginger syrup is prepared and sold by
New Chapter Inc (Brattleboro, Vt). The
company also prepared the placebo syrup
and provided both syrups free of charge
Knight 2001
Methods Subject- and observer-masked RCT.
Participants 55 pregnant women, gestation between 6 and 10 weeks.
Interventions Acupuncture - fully described.
Sham with a cocktail stick.
15 minute treatments, twice in the first week and once weekly for 2 weeks, minimum
number of treatments was 3
Outcomes Primary outcomes measured using a 100 mm visual analogue scale - marked no nausea
to nausea worst imaginable. Completed the scale daily to represent the worst experience
of nausea in the previous 24 hours. Also recorded number of times they vomited in past
24 hours; plus adverse effects
Hospital Anxiety and Depression Scale as a secondary measure - at baseline and imme-
diately after the last treatment
Overall effectiveness - within 2 weeks completion of treatment, using 5-point LIkert-
type: much worse (1) to very much better or cured (5)
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Knight 2001 (Continued)
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Participants randomly assigned to 2 groups.
Computer-generated random numbers, strati-
fied for severity of nausea, randomisation in
blocks of 4. It may be possible to predict ran-
domisation sequence in small blocks
Allocation concealment? Yes By opening opaque sequentially numbered en-
velopes containing codes
Blinding?
Change in grade of nausea or vomiting at
second visit compared to first
Yes Women described as masked to allocation (1
woman in each group thought that they had
received sham acupuncture, all others thought
they had had acupuncture); acupuncturist knew
treatment (not feasible not to); outcome assessors
blinded to group allocation
Incomplete outcome data addressed?
Change in grade of nausea or vomiting at
second visit compared to first
Yes Acupuncture group: 5 people dropped out for no
reason and 1 was admitted for hyperemesis
Sham acupuncture group: 1 withdrew consent
before treatment; 2 dropped-out for no reason,
1 had a missed abortion and 1 was admitted for
hyperemesis. ITT analysis performed
Free of selective reporting? Yes Number of vomiting episodes not reported; state
that women failed to record systematically data
on vomiting
Median scores reported only (data not normally
distributed; failed Mauchly’s test of sphericity).
Median rating of 4 (range 3-5) for global effec-
tiveness for both groups, reported by the authors
as “indicating an overall level of satisfaction with
the treatment”, implying satisfaction with sham
treatment also
Free of other bias? Yes Authors state limitation of availability of
acupuncturist, variable times between treatments
for some women. Sham procedure might have
placebo effects (A-delta fibres stimulated)
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McGuiness 1971
Methods Double-blind comparison. Tablets supplied in bottles serially numbered from 1 to 100
and each contained 28 tablets, either the active product or lactose
Participants Pregnant women who complained of nausea and vomiting in the first trimester; no
women admitted to the trial after 20 weeks; 1 woman entered the trial twice with 2
pregnancies. General practice setting. Results reported for 41 women in intervention
group, 40 women in control group. It was not stated how many women entered the trial
Interventions Intervention group: Debenox (a mixture of dicyclomine, doxylamine and pyridoxine) 2
tablets at bedtime each night (dose not stated) for 14 consecutive nights
Control group: inert dummy tablets of identical appearance.
Outcomes Change in grade of nausea or vomiting at the second visit compared to the first (time
between visits not specified). Symptomswere graded according to severity betweenGrade
0 and 4 (no explanation or validation information given, no sources cited)
Grade 0: no nausea or vomiting (only applicable on the second visit);
Grade 1: slight nausea only which is acknowledged only on questioning;
Grade 2: more severe nausea complained of by the patient spontaneously;
Grade 3: vomiting once or twice a day;
Grade 4: more severe vomiting 3 or more times a day.
Side effects were also reported - though these were not mentioned as being measured
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? No Nothing stated about randomisation.
Allocation concealment? Yes Implied “A sealed code was available to us
in case of emergency but this was not bro-
ken throughout the course of the trial, since
no untoward reactions occurred”
Blinding?
Change in grade of nausea or vomiting at
second visit compared to first
Yes The trial was described as a “double blind”
comparison. Appears women, doctors and
independent observer collecting data were
blinded
The control group received “inert dummy
tablets of identical appearance”. “The
tablets were supplied in bottles serially
numbered from 1 to 100 and each con-
tained 28 tablets, either the active product
or lactose. A sealed code was available to
us in case of emergency but this was not
broken throughout the course of the trial,
since no untoward reactions occurred.”
“The data was [sic] collected by an inde-
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McGuiness 1971 (Continued)
pendent observer with training in medical
statisticswho assessed the results ’blind’ and
commented impartially on the outcome of
the study.”
Incomplete outcome data addressed?
Change in grade of nausea or vomiting at
second visit compared to first
No No information of number of women who
entered the trial so it is not possible to es-
tablish of there was any attrition; no miss-
ing data information at all
Free of selective reporting? Yes Reports on pre-specified outcome.
Free of other bias? Unclear Within the introduction the authors state
that Debenox had been in use for many
years in their practice and that “the absence
of untoward side actions with ’Debenox’,
in particular teratogenesis, has been amply
demonstrated by the passage of 12 years”
“Thanks are due to Dr J. P. Birkett, Merrell
Division, Richardson-Merrell Limited for
supplies of inert and active tablets, statisti-
cal aid and secretarial help.”
Newlinds 1964
Methods Clinical trial.
Participants 225 pregnant women in the first and 2nd trimesters of pregnancy
Interventions Thiethylperazine 30 mg daily.
Placebo.
Outcomes Therapeutic response: good, fair, poor. No information on time-point of evaluation(s)
Notes The patients were not told they were taking part in a trial.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Not described.
Allocation concealment? Unclear Staff reported to be blind to group allocation - not described
how
Blinding?
Change in grade of nausea or vomiting at
second visit compared to first
Yes The staff of the clinic did not know which of the 2 apparently
similar tables the patient would receive
Double-blind trial.
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Newlinds 1964 (Continued)
Incomplete outcome data addressed?
Change in grade of nausea or vomiting at
second visit compared to first
Yes High attrition: 45 (20% of 225, 19 from treatment group, 26
from placebo group) were not included in the analysis because
of failure to return for assessment, transfer to another hospital
or failure to take the tablets (breakdown by reason not given)
. Results about therapeutic response reported for 180 patients
(but 8 from treatment group and 8 from placebo group were not
classified “because of equivocal evidence, intercurrent illness or
abortion”), results for fetal outcome reported for 147 patients
Free of selective reporting? Yes All outcomes reported.
Free of other bias? Yes
Norheim 2001
Methods Randomised controlled trial.
Participants 97 pregnant women, 6-12 weeks’ gestation, with nausea for at least 1 week before trial
entry
139 women responded to the study invitation, 97 women took part (symptoms disap-
peared, too ill, too late in pregnancy)
Interventions Acupressure group: wristbands (with button/knob on the inside) day and night on
Neigun point of both arms
Placebo group: wristband (with felt patch in stead of button) identical on the outside to
acupressure band
4 day run-in, 4 day intervention, 4 day follow up.
Outcomes Symptoms of nausea and vomiting recorded daily - 3 recordings
What problems they had: no problems, nausea, vomiting.
How many hours they had suffered.
Every evening an overall evaluation of their symptoms on a Visual Analogue Scale (0-5
no problems to worst thinkable level of nausea and vomiting)
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Block randomisation in blocks of 20.
Allocation concealment? Unclear Not stated.
Blinding?
Change in grade of nausea or vomiting at
second visit compared to first
Yes A study assistant instructed the women in the use of the
wristbands (investigators blinded)
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Norheim 2001 (Continued)
Incomplete outcome data addressed?
Change in grade of nausea or vomiting at
second visit compared to first
Yes All 97 participants reported on in results: 13 women
who did not complete all of the daily forms were as-
signed values equivalent to the last reported value on the
outcome variables
Free of selective reporting? Unclear Unclear about numbers per group in results tables (%s
presented)
Free of other bias? Yes The authors highlight potential selection, information
and performance of intervention bias - but these appear
to be no greater than for other similar studies
O’Brien 1996
Methods Randomised controlled trial.
Participants 161 women with symptoms of nausea with or without vomiting and retching during
pregnancy.Gestational age formost (78.6%)womenwas < 12weeks,maximumgestation
24 weeks (not stated for how many)
Interventions P6 (Neiguan) acupressure group - band applied for 5 days, removed morning of day 6
Placebo acupressure group (acupressure band inappropriately placed)
Control group - no treatment.
7-day study.
Outcomes Symptoms of nausea and vomiting, using Rhodes Inventory of Nausea and Vomiting
(Form 2), measuring prevalence and amount of distress caused by symptoms over 12
hour period, recorded twice daily from entry to the study to 6 days later
Notes Gestation up to 23.6 weeks; no raw usable data provided.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Use of a process of block randomisation (size of blocks
not specified), computer generated
Allocation concealment? Yes The blocks of group assignments were computer gen-
erated and placed in numbered sealed envelopes before
the study began. Participants were given numbers that
corresponded with their envelope numbers and this was
determined by the order in which they entered the study
Blinding?
Change in grade of nausea or vomiting at
second visit compared to first
Yes Only participants randomised to the control group were
aware of their group assignment
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O’Brien 1996 (Continued)
Incomplete outcome data addressed?
Change in grade of nausea or vomiting at
second visit compared to first
Yes 12 participants withdrew at various times during the
study (5 lost of interest in evaluating their symptoms
during the study, 3 for disappointment at being assigned
to control group, 2 were hospitalised for severe symp-
toms and 4 refused to discontinue the intervention at
the appropriate time)
Free of selective reporting? Unclear Results reported graphically only, as mean squares.
Free of other bias? Yes
Ozgoli 2009
Methods Single-blind RCT.
Participants 70 pregnant women under 20 weeks’ gestational age, without any surgical or medical
history, without a history of smoking or drug use, and with mild or moderate nausea
with or without vomiting were recruited to the study
Interventions Treatment group: 1 g ginger daily (as 4, 250 mg ginger capsules, 1 capsule morning,
noon, afternoon and night) for 4 days
Control group: placebo capsules, similar in appearance to ginger capsules, containing
only lactose, for 4 days
Outcomes Nausea severity and intensity on 0-10 VAS twice daily; number of vomiting episodes
daily; general changes to nausea and vomiting recorded during interview with researcher
after 4 days of treatment
Adherence to dietary advice was also recorded and assessed by interview after day 4
The incidence of unspecified “complications” was also recorded
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Randomly assigned, no details given.
Allocation concealment? Unclear Stated that the experimental group was matched with the con-
trol group regarding demographic and obstetrical characteristics.
The results section states that matching groups on these char-
acteristics did not reveal any significant differences between the
two, so maybe matching relates to comparisons after allocation
Blinding?
Change in grade of nausea or vomiting at
second visit compared to first
No Described as single blinded study. Participants were blinded to
the content of the capsules. Researchers not blinded. Researchers
were involved in aspects of outcome assessment- no blinding
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Ozgoli 2009 (Continued)
Incomplete outcome data addressed?
Change in grade of nausea or vomiting at
second visit compared to first
Yes 67 women completed the study; 3 from the experimental group
failed to complete the after-treatment questionnaire
Free of selective reporting? Unclear Results reported unclearly; daily scores/results not presented,
presented by number of assessments, not participants. Overall
percentage improvement by group then reported in the text; un-
clear if this is based on overall assessment on day 5, or assessment
of change in scores
Pongrojpaw 2007
Methods Randomised controlled trial.
Participants 170 pregnant women less than 16 weeks’ gestation, with symptoms of nausea and vom-
iting
Interventions Group A: received 1 ginger capsule (0.5 g ginger powder) twice daily
Group B: identical capsule of 50 mg dimenhydrinate twice daily
Outcomes Primary outcome: improvement in nausea and vomiting symptoms. Degree of nausea
measured using a 10 cm visual analogue scale to grade the severity of nausea over past
24 hours on first visit; on the following 7 days of treatment recordings were made twice
daily in the morning and evening
Number of episodes of vomiting recorded daily.
Secondary outcomes: occurrence of side effects such as drowsiness, heartburn, palpitation
and mouth dryness
Notes Results difficult to interpret.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Randomly allocated - no detail.
Allocation concealment? Unclear Not described.
Blinding?
Change in grade of nausea or vomiting at
second visit compared to first
Yes Identical capsules used; no other details; blinding im-
plied.
Incomplete outcome data addressed?
Change in grade of nausea or vomiting at
second visit compared to first
Yes 11% attrition: 8 women from ginger group and 11
women from dimenhydrinate group were lost to follow
up (no further details given)
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Pongrojpaw 2007 (Continued)
Free of selective reporting? Unclear Unclear reporting of results; many tests. Explained tests
due to high variation in pre-intervention scores
Free of other bias? Yes
Price 1964
Methods A double-blind placebo-controlled study.
Participants 78 patients complaining of nausea or vomiting in pregnancy, gestation was over 20 weeks
for some participants:
13-24 weeks’ gestation: 8 in treatment group, 4 in placebo.
25-36 weeks: 6 in placebo group.
Not specified: 1 in placebo group.
Interventions Treatment group: fluphenazine 1 mg (repeat action tablet) plus 50 mg pyridoxine
Placebo: identically appearing placebo tablets.
Outcomes Intensity of nausea and vomiting graded by women at outset and at the conclusion of 1
week of therapy. 6-point scale (0-6) ranged from no nausea or vomiting (0) to vomiting
more than 3 times/day (6). Initial symptoms: 1-2 classified as mild, 3-4 as moderate and
5-6 as severe. Effectiveness was measured by deducting the post-treatment score from the
initial score - therapeutic response for each category of initial symptoms is expressed as
excellent, good or poor by proper assignment of numerical values (based on their initial
score)
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Investigator bias is eliminated by the pro-
vision of a numbered series of bottles
in which drug and identically appearing
placebo tablets are randomly distributed; no
details of how randomised
Allocation concealment? Unclear Not described - patients were given 1 of suc-
cessively numbered bottles in the series
Blinding?
Change in grade of nausea or vomiting at
second visit compared to first
Yes Blinding implied - identities of the coded
tablets revealed after outcome data collected
Incomplete outcome data addressed?
Change in grade of nausea or vomiting at
second visit compared to first
Yes All participants included in reported results.
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Price 1964 (Continued)
Free of selective reporting? Yes Outcomes reported according to classifica-
tion.
Free of other bias? Yes Later gestation of some participants in
placebo group.
Puangsricharern 2008
Methods RCT.
Participants 98 pregnant women with symptoms of nausea and vomiting, of not more than 14 weeks’
gestation were recruited; exclusion criteria: women with molar pregnancy, multifetal
pregnancy, blighted ovum, hyperemesis gravidarum, or current use of anti-emetic med-
ication
Interventions Treatment group: auricular acupuncture, using round magnetic balls as ear pellets. These
were placed with adhesive tape at the auricles of both ears (on auricular point at inner
surface of auricle at the concha ridge zone, according to the meridians of Traditional
Chinese Medicine). Women in this group were instructed to start pressing the magnets
for 30 seconds 4 times a day (before meals and at bedtime), starting on the third day
until the 6th day. First 2 days used as control days
Control group: no treatment, except oral anti-emetic drugs (as below)
Both groups were allowed to take 1 tablet of 50mg dimenhydrinate every 6 hours as
required if they could not tolerate their symptoms; remaining tablets were counted at
end of 1 week of the study
Outcomes Frequency, duration and distress of nausea and vomiting and retching symptoms was
measured using the Rhodes Index (range 0-32, 8 5-point self-report items); completed
every morning for 6 days. Scores from day 4-6 used to measure treatment effect
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Patients were randomised using a random table of numbers.
Allocation concealment? Unclear No details stated.
Blinding?
Change in grade of nausea or vomiting at
second visit compared to first
No No blinding. Did not use placebo on ear due to stated limited
area on the ear and possibility of affecting the treatment point;
self-reporting of outcomes
Incomplete outcome data addressed?
Change in grade of nausea or vomiting at
second visit compared to first
Yes 91 patients completed the study. 7 patients lost to follow up, 4
in the treatment group, 3 in the control group. No explanation
given
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Puangsricharern 2008 (Continued)
Free of selective reporting? Yes All outcomes reported. Stated in results section that no one in
treatment group experienced any adverse effect from acupres-
sure and satisfaction with treatment is also reported as (% of
treatment group satisfied). Adverse effects and satisfaction not
stated as outcomes to be measured
Free of other bias? Unclear Differences between groups on education, income and occupa-
tion within baseline characteristics reported (women in control
group were more educated, higher income and a higher percent-
age were housewives, in the occupational category)
Rosen 2003
Methods RCT.
Participants 230 pregnant women with symptoms of mild to severe nausea and vomiting between 6
and 12 weeks’ gestation
Interventions Nerve stimulation therapy at the P6 acupuncture point, via a wristband
Placebo: identical but non-stimulating device.
Outcomes Primary outcomes - assessment of nausea and vomiting, self-recorded symptoms accord-
ing to the Rhodes Index of Nausea, Vomiting and Retching; data collected on 12 days
of the 21 day study, days 1-7, 9, 11, 13, 17 and 21
Secondary outcomes - weight gain or loss, change in urinary ketones and specific gravity
and medication use
Notes Some results (changes in scores over time) in graphical form only
Includes participants with mild to severe symptoms; does not present result separately
for each group. Miller 2001 presents results for participants with severe symptoms only
(73 of the 193 total). De Veciana 2001 [abstract] reports mild/moderate vs severe- not
reported in Rosen 2003 [main/only full paper].
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer-generated list.
Allocation concealment? Yes Sequentially numbered opaque, sealed envelopes.
Blinding?
Change in grade of nausea or vomiting at
second visit compared to first
Yes Participants were blinded (to preserve blinding, patients were
told that they may or may not feel a tingling sensation), study
personnel and those assessing outcomes were not blinded. Be-
cause of the subjects’ different responses to active and sham de-
vices, it was not possible to blind study personnel. Unlikely to
introduce bias, as self-reporting
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Rosen 2003 (Continued)
Incomplete outcome data addressed?
Change in grade of nausea or vomiting at
second visit compared to first
Unclear 187 women completed the trial; high attrition - 43 patients did
not complete the study (18.6%), 22 in treatment group and 21
in the control group. Patients who withdrew were more likely
to be multiparous and to have ketonuria. 3 patients from each
group withdrew due to adverse events, only 1 attributable to the
device. Patients were excluded if they completed fewer than 9
form sets (from total of 23). 4 patients in the treatment group
and 1 patient in the control group were “non-compliant”
Free of selective reporting? Yes Results not reported by subgroup (based on severity) in the full
paper available for this study
Free of other bias? Yes
Sahakian 1991
Methods Randomised, double-blind placebo-controlled study.
Participants 74 pregnant women consented to participate; 59 women completed the protocol
Interventions Treatment group: vitamin B6 - 25 mg tablets every 8 hours for 72 hours
Placebo: identical appearing tablets to be taken using the same regimen
Outcomes Severity of nausea: marked on 10 cm unmarked Visual Analogue Scale: 0 as no nausea
and 10 as worst possible nausea; recorded by women 4 times daily (am, noon, pm,
bedtime) for the 3 days of treatment
Number of episodes of emesis per 24 hours recorded daily for 3 days
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Randomised by a table of numbers.
Allocation concealment? Unclear Not described.
Blinding?
Change in grade of nausea or vomiting at
second visit compared to first
Yes All individuals involved in the study except
for the pharmacist were blinded to the na-
ture of the medication
It is not clear at what stage group allocation
became known.
Incomplete outcome data addressed?
Change in grade of nausea or vomiting at
second visit compared to first
Unclear 20.2% drop-out rate high, not clear which
group attrition was in
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Sahakian 1991 (Continued)
Free of selective reporting? Unclear After data collection but before data analy-
sis, the authors say that they arbitrarily di-
vided the patients into 2 subgroups accord-
ing to the severity of their nausea - patients
with a nausea score of greater than 7 were
in the severe nausea group and those with
scores less than or equal to 7 were cate-
gorised in the mild to moderate subgroup
and these 2 groups were then compared. As
the results showed that there was a signifi-
cant improvement in the severe nausea sub-
group who received the intervention, bias
in the arbitrary post hoc cut-off for severity
subgroup bias cannot be ruled out
Unclear reporting - average of averages,
mean change from baseline (standard error
of the difference in the means) etc
Free of other bias? Yes
Smith 2002
Methods RCT.
Participants 593 women less than 14 weeks’ gestation with symptoms of nausea or vomiting
Interventions Traditional acupuncture group (traditional diagnosis and then acupuncture to selected
points)
P6 acupuncture group (Pericardium point on wrist only).
Sham acupuncture group (to points near true points).
No acupuncture (control) group (general advice and phoned and asked about their well-
being). The authors state that to reduce disappointment when women were allocated to
the control group, a standardised information sheet was made available about advice on
diet, lifestyle and the use of vitamin B6 during the 4-week study period. Not stated if all
women got this advice (including about vitamin B6)
Treatment was administered weekly for 4 weeks from all 3 acupuncture groups. Very
detailed descriptions given
Outcomes Primary outcomes: nausea, vomiting, dry retching at days 7, 14, 21 and 26 (measured
by the Rhodes Index of Nausea and Vomiting Form 2) and health status on days 1, 14
and 28 (measured by MOS 36 Short Form Health Survey (SF36))
Pregnancy outcomes: perinatal outcome, congenital abnormalities, pregnancy compli-
cations and infant outcomes
Notes Related 2 articles report pregnancy outcomes and placebo response and effect of time
and related abstract reports women’s experiences of nausea (data collected prior to ran-
domisation from 253 women)
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Smith 2002 (Continued)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Randomisation sequence in variable balanced blocks.
Allocation concealment? Yes Centralised, external telephone randomisation service.
Blinding?
Change in grade of nausea or vomiting at
second visit compared to first
Yes Women in acupuncture and sham acupuncture groups were
blinded - asked to guess which group they were in (84% guessed
correctly that they were in Traditional Acupuncture group, 77%
P6 Acupuncture and 41% Sham Acupuncture) (reported un-
clearly in Table 4 in Smith & Crowther 2002). They were asked
why they guessed what they did and this was also related by the
study investigators to their beliefs about acupuncture. Authors
acknowledge that the trial was advertised in the media, which
sensationalised the trial, for example, under the heading “morn-
ing sickness cure”
Incomplete outcome data addressed?
Change in grade of nausea or vomiting at
second visit compared to first
Yes 24% attrition by week 4; number of forms (nausea and vomiting
and SF36) not completed and number of pregnancy losses per
group stated described in detail
Free of selective reporting? Unclear Many results reported (mean differences not reported).
Free of other bias? Unclear Vitamin B6 advice given to control group not clear whether to
others also
Smith 2004
Methods Randomised controlled equivalence trial.
Participants 291 women with nausea or vomiting, less than 16 weeks’ pregnant
Interventions Ginger 1.05 g daily (1 capsule of ginger 350 mg 3 times a day)
Vitamin B6 daily (1 capsule vitamin B6 25 mg 3 times a day).
Treatment was for 3 weeks to test whether ginger and vitamin B6 were equivalent in
treating symptoms
Outcomes Equivalence and examined any change in nausea and vomiting scores, measured at days
7, 14 and 21, measured using the Rhodes Index of Nausea and Vomiting Form 2. They
recorded baseline for 3 days before randomisation
Health status measured using the MOS 36 Short Form Health Survey, recorded at
baseline and day 21
Secondary outcomes: occurrence of any side effects and adverse pregnancy outcomes
Notes
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Smith 2004 (Continued)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Women were randomly assigned by log-
ging on to the service at a Trials Unit; the
computer-generated randomisation sched-
ule used balanced variable blocks and was
prepared by a researcher not involved in the
trial
Allocation concealment? Yes Centralised system as above, capsules con-
tained in opaque envelopes
Blinding?
Change in grade of nausea or vomiting at
second visit compared to first
Yes Identical capsules. Data entry personnel
blinded.
Data available on blinding from women -
40% unsure about which group they be-
longed to (76% from ginger group and 65%
of B6 group correctly guessed which group
they were in)
Incomplete outcome data addressed?
Change in grade of nausea or vomiting at
second visit compared to first
Yes Loss to follow up in ginger group (n = 146)
was 26 and vitamin B6 group (n = 145) was
30
Free of selective reporting? Yes Does not appear to be any.
Free of other bias? Yes
Sripramote 2003
Methods Double-blind RCT.
Participants 138 women with nausea and vomiting of pregnancy at or before 16 weeks’ gestation
Interventions Ginger 500 mg orally (1 capsule) 3 times daily for 3 days.
Vitamin B6 10 mg daily (1 capsule), identical to ginger capsule 3 times daily for 3 days
(used as a positive control for ethical reasons)
Outcomes Primary outcomes: improvement in nausea symptoms, measured using 10 cm Visual
Analogue Scale (0 as no nausea to 10 as nausea as bad as it could be)
Number of vomiting episodes also recorded. Other secondary outcomes: occurrence of
side effects such as drowsiness, palpitations, heartburn and mouth dryness
Notes
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Sripramote 2003 (Continued)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes A pharmacist not responsible for patient care used a table of
random numbers to prepare the treatment assignment by ran-
domisation with a block of 4 to receive ginger or vitamin B6
Allocation concealment? Yes The treatment codewas concealed by placing the patient’s assign-
ment in sequence in sealed opaque envelopes that were drawn
in ascending consecutive order
Blinding?
Change in grade of nausea or vomiting at
second visit compared to first
Yes Codes were kept concealed until the end of the study.
Incomplete outcome data addressed?
Change in grade of nausea or vomiting at
second visit compared to first
Yes 4 cases in the ginger and 6 cases in the vitamin B6 group did
not return for follow up; 64 evaluable in each group
Free of selective reporting? Yes No selective reporting apparent.
Free of other bias? Yes
Vutyavanich 1995
Methods Randomised double-blind placebo-controlled trial.
Participants 342 pregnant women at </= 17 weeks’ gestation.
Interventions Oral pyridoxine (vitamin B6) received 20 10 mg tablets to be taken every 8 hours (6-8
am, 2-4 pm, 10 pm-12 md) for 5 days
Placebo: identical-looking tablets to be taken in the same regime
Outcomes Primary outcome: change in the secondary outcome severity of nausea; measured in a
Visual Analogue Scale in centimetres (10 cm 0 as no nausea to 10 as nausea as bad as
it could be). Average daily nausea scores calculated and then mean nausea score over 5
days
Secondary outcome: change in the number of vomiting episodes
Notes
Risk of bias
Item Authors’ judgement Description
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Vutyavanich 1995 (Continued)
Adequate sequence generation? Yes Patients were then randomised into 2
groups by a table of random numbers
Allocation concealment? Yes A list that revealed drug codes was kept by
the research assistant and was not accessible
to the physicians
Blinding?
Change in grade of nausea or vomiting at
second visit compared to first
Yes Pyridoxine and placebo tablets were pre-
pared by the hospital pharmacy and packed
similarly in envelopes in an envelope con-
taining 20 tablets each.Neither the patients
nor the physicians knew the identity of
the drugs administered. A list that revealed
drug codes was kept by the research assis-
tant and was not accessible to the physi-
cians
Incomplete outcome data addressed?
Change in grade of nausea or vomiting at
second visit compared to first
Yes All included in analysis except 6 who did
not return for follow up (2 in placebo
group, 4 in treatment group)
Free of selective reporting? Yes All outcomes reported.
Free of other bias? Yes No other sources of bias apparent.
Vutyavanich 2001
Methods Randomised double-masked placebo-controlled trial.
Participants 70 women with nausea and vomiting of pregnancy before 17 weeks’ gestation (88 eligible
for inclusion, 70 agreed to participate)
Interventions Ginger 1 g daily orally (250 mg capsules 4 times per day, 3 after meals and 1 before bed)
; capsules prepared from ginger roots (preparation described)
Placebo - identical capsules.
Treatment was for 1 week.
Outcomes Primary outcome: improvement in nausea symptoms. Severity of nausea recorded a 10
cm visual analogue scale 0 as no nausea, 10 as nausea as bad as could be; twice daily (noon
and evening) for 4 days. Average daily scores and mean score over 4 days calculated
Number of vomiting episodes daily recorded.
At follow up 1 week after treatment overall severity was measured using a 5-point Likert
scale (much worse, worse, same, better, much better)
Occurrence of side effects and adverse effects on pregnancy outcomes also recorded: such
as abortion, preterm birth, congenital anomaly, perinatal death and mode of delivery
Notes
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Vutyavanich 2001 (Continued)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes A research nurse who was not responsi-
ble for patient care used a table of random
numbers to prepare the treatment assign-
ment
Allocation concealment? Yes The treatment codes were kept in sequence
in a sealed black envelope that could not
be read through. As each subject entered
the trial, she received the next envelope in
the sequence which determined her assign-
ment
Blinding?
Change in grade of nausea or vomiting at
second visit compared to first
Yes Neither the patients nor the physicians
knew the identity of the drugs administered
Incomplete outcome data addressed?
Change in grade of nausea or vomiting at
second visit compared to first
Yes Lownumber of women lost to followup (3,
all in placebo group, included in the anal-
ysis, assuming symptom relief equal to the
best improvement in the placebo group)
Free of selective reporting? Yes All outcomes reported.
Free of other bias? Yes No other sources of bias identified.
Werntoft 2001
Methods Randomised placebo-controlled pilot study.
Participants Pregnant women with normal pregnancy and nausea and vomiting of pregnancy
Results presented for 60 women - 80 envelopes had been distributed by the time 20
women in each group, totally 60 women or 75% had returned the envelopes (12 of the
20 explained, 8 missing, unknown group)
No clear gestational criteria set, 1 woman after 6 weeks’, 1 after 16 weeks’ gestation
and most (n = 34) entered the study after 9-11 weeks’ gestation; there was a statistically
significant difference in mean gestational age by group (control group highest)
Interventions Acupressure at the P6 (Neigun) point, using wristbands with a button; worn daily for 2
weeks, only removing it when showering
Acupressure at a placebo point, wristband with a button, applied at upper side of wrist;
worn daily for 2 weeks
Control group - no acupressure.
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Werntoft 2001 (Continued)
Outcomes 100 mm visual analogue scale with anchors at each end to indicate the extremes of the
sensation under study (no nausea to extreme nausea). Recorded before treatment, on day
1, after 3 days, after 6 days and after 14 days
Incidence of vomiting also reported - not described as an outcome of interest
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Only description: women drew an enve-
lope from a box, envelopes had the same
appearance but different contents
Allocation concealment? Unclear Only description: women drew an enve-
lope from a box, envelopes had the same
appearance but different contents
Blinding?
Change in grade of nausea or vomiting at
second visit compared to first
Yes Women did not open the envelope until
they got home; blinding possible only if in
1 of 2 acupressure (P6 or placebo) groups;
this then presumes no prior knowledge of
acupressure (not stated)
Incomplete outcome data addressed?
Change in grade of nausea or vomiting at
second visit compared to first
Unclear Study stopped when 20 completed ques-
tionnaires per group were received - states
about 80 envelopes were given out - not
clear how many per group were given out.
From the 20 not completed, 12 are ex-
plained: 6 questionnaires from the P6 and
placebo groups were excluded due to in-
completeness, 4 women found the wrist-
band too tight to use and 2 women had
miscarriages. 8women did not respond and
it was not possible to identify which group
they belonged to (implies did not know
how many in each group were given out)
Free of selective reporting? Yes All outcomes reported.
Free of other bias? Yes
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Willetts 2003
Methods Double-blind randomised placebo-controlled trial.
Participants 120pregnantwomen less than20weeks’ gestationwhohad experiencedmorning sickness
for at least 1 week with no relief through dietary changes
Interventions 125 mg ginger extract (EV.EXT35, equivalent to 1.5 g dried ginger)
Placebo, containing soya bean oil in identical wax-sealed capsules
4 times/day (8 am, 12 noon, 4 pm, 8 pm) 4 days.
Outcomes Primary outcomes: nausea experience.
Secondary outcomes: other 8 scores.
Nausea, vomiting, retching as measured by the Rhodes Index of Nausea, Vomiting and
Retching (RINVR) (8-item 5-point Likert-type tool, measuring frequent, duration and
distress caused by symptoms)
Recorded 1 hour after capsule was taken, for baseline day and 4 days of treatment
Side effects and adverse events also reported.
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes The random allocation sequence was gen-
erated by Eurovita Pty Ltd Denmark using
randomblocks of 6 andwas placed in sealed
envelopes and posted to the researchers
Allocation concealment? Yes Sealed envelopes.
Blinding?
Change in grade of nausea or vomiting at
second visit compared to first
Yes Participants, those administering the treat-
ment and those assessing the outcomes
were all blinded to the group assignment
Incomplete outcome data addressed?
Change in grade of nausea or vomiting at
second visit compared to first
Yes 21 women excluded from final analysis due
to insufficient data: 12 for adverse events
(details given) and 9 for non-compliance
Free of selective reporting? Unclear Mostly report the primary outcome (nausea
experience), little reported on vomiting and
retching
Results displayed in graphs only, no raw
(usable) data.
Free of other bias? Unclear Eurovita funded the study, generated the
allocation sequence and manufactured the
ginger extract 9EV.EXT35)
Stated inDiscussion that treatment contin-
ued for ginger group for 8 days and placebo
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Willetts 2003 (Continued)
took ginger for 4 days and all were given
2 weeks’ supply following the end of the
trial. Only the data for 4 days was analysed,
hence the findings of the follow-up assess-
ment (for the 81 women who completed
themain study) should be viewedwith cau-
tion. No direct attempt can be made to in-
fer cause or association between the find-
ings and the use of ginger over the 8-day
period of the principal study
IM: intramuscular
ITT: intention to treat
RCT: randomised controlled trial
VAS: Visual Analogue Scale
vs: versus
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Baum 1963 Quasi-randomised, alternate allocation of patients to groups
Bayreuther 1994 Crossover design.
Can Gurkan 2008 Planned as a randomised study, but not carried out as planned (patients on each day placed in same group)
Cartwright 1951 Crossover design.
Conklin 1958 Not randomised, patients “arbitrarily allocated” to groups.
De Aloysio 1992 Crossover design.
Diggory 1962 Quasi-randomised “each patient in sequence was allocated”; control group reallocated if not improving
Dundee 1988 Not an RCT; women allocated to groups by day of the week; non-responders replaced in treatment group
Evans 1993 Crossover design.
Ferruti 1982 This is a study of hypocorticalism in pregnancy.
Fitzgerald 1955 Not an RCT; alternate allocation of patients.
Heazell 2006 Severe symptoms, in-patient; hyperemesis gravidarum implied (severe symptoms plus ketonuria)
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(Continued)
Higgins 2009 Hyperemesis gravidarum (day care versus in-patient management; trial registry record only, no data)
Hyde 1989 Crossover design.
Kadan 2009 Hyperemesis gravidarum as specified condition of participants (RCT, with crossover if first drug allocated not
effective: thiamine 100mg IV or promethazine 25mg IV; started February 2009, trial registry record only,
ongoing at May 2010)
King 1955 Type of crossover design.
Koren 2006 Pre-emptive treatment; not treating symptoms.
Lask 1953 Not an RCT.
Luz 1987 No data available; this is a communication of a planned trial - a search identified no further publications from
this study
Steele 2001 Quasi-experimental design posttest-only and post-test repeated measure
Wheatley 1977 Crossover design.
Winters 1961 Quasi randomised trial - “test material and placebo were strictly alternated”
IV: intravenous
RCT: randomised controlled trial
Characteristics of studies awaiting assessment [ordered by study ID]
Adamczak 2007
Methods Prospective randomised trial.
Participants 110 pregnant women with gestation of 8 to 14 weeks.
Interventions Solumedrol dose pack (tapered) versus phenergan.
Outcomes Weight, number of episodes of emesis per day, pregnancy outcome
Notes The authors report that the solumedrol group had significantly fewer emesis episodes that the phenergan group on
days 3, 7, 14
Abstract only; no full text reference/article retrieved; unable to contact authors. Insufficient detail to include this
study
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Biswas 2006
Methods A single-masked randomised controlled trial.
Participants 78 pregnant women with gestation of 6 to 16 weeks (63 completed the study)
Interventions Ginger extract (dose not stated) versus doxylamine succinate plus pyridoxine
Outcomes Severity and frequency of nausea; subjective feeling of well-being; type of delivery; neonatal complications and
abnormality
Notes The authors state that there was no statistical difference between groups on outcomes measured, though sample size
was inadequate. They state that the tolerability and compliance of ginger were more satisfactory with no adverse
event in mother or fetus, but they do not give any further details about this
Abstract only - no full text reference/article retrieved; unable to contact authors. Insufficient detail to include this
study
Hsu 2003
Methods Prospective double-blinded randomised controlled trial.
Participants 77 pregnant women attending the ED.
Interventions P6 Acupressure versus sham acupressure, via a wristband.
Outcomes Nausea severity (using the McGill Nausea Questionnaire), measured at baseline, 30 and 60 minutes
Subsequent anti-emetic administration, length of ED stay.
Notes The authors report that no differences between groups were reported at any time point
Abstract only - no full text reference/article retrieved; unable to contact authors. Insufficient detail to include this
study
Mamo 1995
Methods Prospective randomised trial.
Participants 38pregnantwomen infirst trimester presentingwith severe pregnancy vomiting (not stated if hyperemesis gravidarum)
; title of abstract states “early pregnancy nausea and vomiting”
Interventions Acupressure via sea-band device on both wrists versus control (counselled and dietary advice)
Outcomes Anti-emetic drug use, hospitalisation.
Notes The authors only report higher levels of anti-emetic medication usage for the control group (37%) than the acu-
pressure group (11%) and that there was no significant difference in hospitalisation. However they do not state the
denominators for the groups
Abstract only - no full text reference/article retrieved; unable to contact authors. Insufficient detail to include this
study
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ED: emergency department
Characteristics of ongoing studies [ordered by study ID]
Nguyen 2008
Trial name or title The efficacy of Diclectin for nausea and vomiting in pregnancy
Methods Double-blind, multicenter, randomised, placebo-controlled trial
Participants Pregnant females, 18 years and older, gestation of pregnancy 7-14 weeks at first dose, suffering from NVP
Pregnancy Unique Quantification of Emesis (PUQE) score >/= 6
Interventions Treatment group: Diclectin (Doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg
Placebo.
Outcomes Symptoms of nausea and vomiting will be measured daily using a standardised (unspecified) questionnaire
Starting date January 2008 (planned end date August 2009); no results available at May 2010
Contact information Hoang Nguyen nvp.Pregnancy@premier-research.com
Notes
Wibowo 2009
Trial name or title Vitamin B6 concentration and treatment in nausea and vomiting of pregnancy
Methods Randomised, double-blind controlled study.
Participants Females with nausea and vomiting of pregnancy, aged 15-40 years; other medical conditions causing nausea
and vomiting of pregnancy outruled. Gestation of pregnancy not specified
Interventions High does of Vitamin B6 versus low dose of vitamin B6 (doses not stated)
Outcomes Primary outcomes: nausea and vomiting score (2 week timeframe)
Secondary outcome: vitamin B6 concentration in nausea and vomiting of pregnancy (2 week timeframe)
Starting date January 2008 (estimated study completion date: October 2008); no results available at May 2010
Contact information Noroyono Wibowo MD PhD, Indonesia, wibowonoroyono@yahoo.com
Notes
ED: emergency department
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D A T A A N D A N A L Y S E S
Comparison 1. P6 Acupressure versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 No improvement in intensity
of symptoms (while using
wristbands) reported
1 97 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.44, 1.39]
2 Mean nausea score after day 3
using VAS
1 40 Mean Difference (IV, Fixed, 95% CI) 0.10 [-1.49, 1.69]
3 Mean nausea score days 1-3
(average)
1 60 Mean Difference (IV, Fixed, 95% CI) 0.39 [-0.80, 1.58]
4 Mean emesis scores days 1-3
(average)
1 60 Mean Difference (IV, Fixed, 95% CI) 0.26 [-1.06, 1.58]
5 Mean total scores (Rhodes
Index) days 1-3 (average)
1 60 Mean Difference (IV, Fixed, 95% CI) 1.17 [-1.52, 3.86]
Comparison 2. P6 Acupressure versus vitamin B6
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Nausea scores on day 3 1 66 Mean Difference (IV, Fixed, 95% CI) 0.20 [-2.24, 2.64]
2 Poor symptom relief/amount of
rescue medication (number of
tablets)
1 60 Mean Difference (IV, Fixed, 95% CI) -2.20 [-3.98, -0.42]
3 Satisfaction rating of
intervention by participants
1 60 Mean Difference (IV, Fixed, 95% CI) 0.40 [-0.04, 0.84]
4 Weight gain from entry date to
end of the trial (kg)
1 66 Mean Difference (IV, Fixed, 95% CI) 0.7 [0.24, 1.16]
Comparison 3. Auricular acupressure versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Nausea/vomiting score
(combined Rhodes Index score)
on day 6 (3 days after treatment
started)
1 91 Mean Difference (IV, Fixed, 95% CI) -3.60 [-6.62, -0.58]
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2 Number of anti-emetic drugs
used on day 6 (3 days after
treatment started)
1 91 Mean Difference (IV, Fixed, 95% CI) -0.10 [-0.37, 0.17]
Comparison 4. Acustimulation therapy at P6 point versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Weight gain (in lbs) over 3 week
period
1 187 Mean Difference (IV, Fixed, 95% CI) 1.7 [0.23, 3.17]
2 Dehydration: occurrences
reported
1 187 Risk Ratio (M-H, Fixed, 95% CI) 0.24 [0.07, 0.83]
3 Ketonuria at the end of the trial 1 187 Risk Ratio (M-H, Fixed, 95% CI) 0.48 [0.15, 1.55]
Comparison 5. Traditional acupuncture versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean nausea score on day 7 1 296 Mean Difference (IV, Fixed, 95% CI) -0.70 [-1.36, -0.04]
2 Mean dry retching score on day
7
1 296 Mean Difference (IV, Fixed, 95% CI) -0.20 [-0.57, 0.17]
3 Mean vomiting score on day 7 1 296 Mean Difference (IV, Fixed, 95% CI) -0.10 [-0.58, 0.38]
Comparison 6. P6 Acupuncture versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean nausea score on day 7 1 296 Mean Difference (IV, Fixed, 95% CI) -0.30 [1.00, 0.40]
2 Mean dry retching score on day
7
1 296 Mean Difference (IV, Fixed, 95% CI) 0.10 [-0.30, 0.50]
3 Mean vomiting score on day 7 1 296 Mean Difference (IV, Fixed, 95% CI) -0.30 [-0.78, 0.18]
62Interventions for nausea and vomiting in early pregnancy (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Comparison 7. Traditional acupuncture versus P6 acupuncture
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean nausea score on day 7 1 296 Mean Difference (IV, Fixed, 95% CI) -0.40 [-1.12, 0.32]
2 Mean dry retching score on day
7
1 296 Mean Difference (IV, Fixed, 95% CI) -0.30 [-0.65, 0.05]
3 Mean vomiting score on day 7 1 296 Mean Difference (IV, Fixed, 95% CI) 0.20 [-0.26, 0.66]
Comparison 8. Ginger versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Improvement in nausea (mean
change score) over 4 days of
treatment: women available to
follow up
1 67 Mean Difference (IV, Fixed, 95% CI) 1.20 [0.22, 2.18]
2 Improvement in nausea (mean
change score) over 4 days of
treatment: ITT analysis
1 70 Mean Difference (IV, Fixed, 95% CI) 0.60 [-0.51, 1.71]
3 Little improvement in nausea 1 23 Risk Ratio (M-H, Fixed, 95% CI) 0.29 [0.10, 0.82]
4 Number of women continuing
vomiting at day 6
1 22 Risk Ratio (M-H, Fixed, 95% CI) 0.42 [0.18, 0.98]
5 Spontaneous abortion 1 67 Risk Ratio (M-H, Fixed, 95% CI) 0.36 [0.04, 3.33]
6 Caesarean delivery 1 67 Risk Ratio (M-H, Fixed, 95% CI) 1.64 [0.51, 5.29]
7 Improvement in nausea intensity
after treatment (day 5)
1 67 Risk Ratio (M-H, Fixed, 95% CI) 1.48 [1.07, 2.04]
Comparison 9. Ginger versus vitamin B6
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Nausea vomiting score day 3 2 251 Std. Mean Difference (IV, Fixed, 95% CI) -0.00 [-0.25, 0.25]
1.1 Rhodes Index 1 123 Std. Mean Difference (IV, Fixed, 95% CI) -0.09 [-0.44, 0.27]
1.2 10 cm VAS 1 128 Std. Mean Difference (IV, Fixed, 95% CI) 0.08 [-0.27, 0.43]
2 Post-treatment number of
vomiting episodes: day 3
1 128 Mean Difference (IV, Fixed, 95% CI) Not estimable
3 No improvement in symptoms 2 360 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.47, 1.52]
4 Spontaneous abortion 2 360 Risk Ratio (M-H, Fixed, 95% CI) 0.49 [0.17, 1.42]
5 Stillbirth 1 291 Risk Ratio (M-H, Fixed, 95% CI) 0.14 [0.01, 2.72]
6 Congenital abnormality 1 291 Risk Ratio (M-H, Fixed, 95% CI) 0.50 [0.13, 1.95]
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7 Antepartum
haemorrhage/abruption,
placenta praevia
1 291 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.29, 3.36]
8 Pregnancy-induced hypertension 1 291 Risk Ratio (M-H, Fixed, 95% CI) 1.24 [0.34, 4.53]
9 Pre-eclampisa 1 291 Risk Ratio (M-H, Fixed, 95% CI) 1.49 [0.43, 5.17]
10 Preterm birth 1 291 Risk Ratio (M-H, Fixed, 95% CI) 1.66 [0.40, 6.80]
11 Arrhythmia 1 123 Risk Ratio (M-H, Fixed, 95% CI) 3.05 [0.13, 73.40]
12 Headache 1 123 Risk Ratio (M-H, Fixed, 95% CI) 0.20 [0.01, 4.15]
13 Heartburn 2 251 Risk Ratio (M-H, Fixed, 95% CI) 2.35 [0.93, 5.93]
14 Sedation or drowsiness 2 251 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.48, 1.19]
15 Caesarean delivery 1 69 Odds Ratio (M-H, Fixed, 95% CI) 0.60 [0.15, 2.36]
Comparison 10. Ginger versus dimenhydrinate
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Drowsiness 1 170 Risk Ratio (M-H, Fixed, 95% CI) 0.08 [0.03, 0.18]
2 Heartburn 1 170 Risk Ratio (M-H, Fixed, 95% CI) 1.44 [0.65, 3.20]
Comparison 11. Vitamin B6 versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean reduction in nausea score
after 3 days
2 393 Mean Difference (IV, Fixed, 95% CI) 0.92 [0.40, 1.44]
2 Number of patients with emesis
post-therapy
2 392 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.35, 1.66]
Comparison 12. Hydroxyzine versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 No relief from nausea 1 150 Risk Ratio (M-H, Fixed, 95% CI) 0.23 [0.15, 0.36]
2 Spontaneous abortion (1st or
2nd trimester)
1 115 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.17, 4.75]
3 Perinatal mortality 1 115 Risk Ratio (M-H, Fixed, 95% CI) 1.39 [0.06, 33.26]
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Comparison 13. Debendox (Bendectin) versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 No improvement of symptoms 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
Comparison 14. Thiethylperazine versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Poor relief from symptoms 1 164 Risk Ratio (M-H, Fixed, 95% CI) 0.49 [0.31, 0.78]
Comparison 15. Fluphenazine-pyridoxine versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Poor response to treatment 1 78 Risk Ratio (M-H, Fixed, 95% CI) 0.52 [0.27, 1.01]
Analysis 1.1. Comparison 1 P6 Acupressure versus placebo, Outcome 1 No improvement in intensity of
symptoms (while using wristbands) reported.
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 1 P6 Acupressure versus placebo
Outcome: 1 No improvement in intensity of symptoms (while using wristbands) reported
Study or subgroup Acupressure Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Norheim 2001 15/53 16/44 100.0 % 0.78 [ 0.44, 1.39 ]
Total (95% CI) 53 44 100.0 % 0.78 [ 0.44, 1.39 ]
Total events: 15 (Acupressure), 16 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.40)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours acupressure Favours placebo
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Analysis 1.2. Comparison 1 P6 Acupressure versus placebo, Outcome 2 Mean nausea score after day 3 using
VAS.
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 1 P6 Acupressure versus placebo
Outcome: 2 Mean nausea score after day 3 using VAS
Study or subgroup P6 Acupressure
Placebo
Acupunc-
ture
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Werntoft 2001 20 5.6 (2.3) 20 5.5 (2.8) 100.0 % 0.10 [ -1.49, 1.69 ]
Total (95% CI) 20 20 100.0 % 0.10 [ -1.49, 1.69 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.90)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours P6 Acupressure Favours Placebo
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Analysis 1.3. Comparison 1 P6 Acupressure versus placebo, Outcome 3 Mean nausea score days 1-3
(average).
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 1 P6 Acupressure versus placebo
Outcome: 3 Mean nausea score days 1-3 (average)
Study or subgroup PC-6 acupressure Placebo acupressure
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Belluomini 1994 30 8.38 (2.2) 30 7.99 (2.5) 100.0 % 0.39 [ -0.80, 1.58 ]
Total (95% CI) 30 30 100.0 % 0.39 [ -0.80, 1.58 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours PC-6 Acupressure Favours Placebo
Analysis 1.4. Comparison 1 P6 Acupressure versus placebo, Outcome 4 Mean emesis scores days 1-3
(average).
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 1 P6 Acupressure versus placebo
Outcome: 4 Mean emesis scores days 1-3 (average)
Study or subgroup PC-6 acupressure Placebo acupressure
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Belluomini 1994 30 2.09 (2.5) 30 1.83 (2.7) 100.0 % 0.26 [ -1.06, 1.58 ]
Total (95% CI) 30 30 100.0 % 0.26 [ -1.06, 1.58 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.70)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours PC-6 Acupressure Favours Placebo
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Analysis 1.5. Comparison 1 P6 Acupressure versus placebo, Outcome 5 Mean total scores (Rhodes Index)
days 1-3 (average).
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 1 P6 Acupressure versus placebo
Outcome: 5 Mean total scores (Rhodes Index) days 1-3 (average)
Study or subgroup PC-6 acupressure Placebo acupressure
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Belluomini 1994 30 12.64 (5.7) 30 11.47 (4.9) 100.0 % 1.17 [ -1.52, 3.86 ]
Total (95% CI) 30 30 100.0 % 1.17 [ -1.52, 3.86 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.39)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours PC-6 Acupressure Favours Placebo
Analysis 2.1. Comparison 2 P6 Acupressure versus vitamin B6, Outcome 1 Nausea scores on day 3.
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 2 P6 Acupressure versus vitamin B6
Outcome: 1 Nausea scores on day 3
Study or subgroup Acupressure Vitamin B6
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Jamigorn 2007 (1) 33 7.8 (3.9) 33 7.6 (6) 100.0 % 0.20 [ -2.24, 2.64 ]
Total (95% CI) 33 33 100.0 % 0.20 [ -2.24, 2.64 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.87)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours Acupressure Favours Vitamin B6
(1) Unpublished data, supllied by study author on request.
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Analysis 2.2. Comparison 2 P6 Acupressure versus vitamin B6, Outcome 2 Poor symptom relief/amount of
rescue medication (number of tablets).
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 2 P6 Acupressure versus vitamin B6
Outcome: 2 Poor symptom relief/amount of rescue medication (number of tablets)
Study or subgroup Acupressure Vitamin B6
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Jamigorn 2007 30 0.6 (1.6) 30 2.8 (4.7) 100.0 % -2.20 [ -3.98, -0.42 ]
Total (95% CI) 30 30 100.0 % -2.20 [ -3.98, -0.42 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.43 (P = 0.015)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours acupressure Favours Vitamin B6
Analysis 2.3. Comparison 2 P6 Acupressure versus vitamin B6, Outcome 3 Satisfaction rating of
intervention by participants.
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 2 P6 Acupressure versus vitamin B6
Outcome: 3 Satisfaction rating of intervention by participants
Study or subgroup Acupressure Vitamin B6
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Jamigorn 2007 30 3 (1) 30 2.6 (0.7) 100.0 % 0.40 [ -0.04, 0.84 ]
Total (95% CI) 30 30 100.0 % 0.40 [ -0.04, 0.84 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.79 (P = 0.073)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours Vitamin B6 Favours Acupressure
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Analysis 2.4. Comparison 2 P6 Acupressure versus vitamin B6, Outcome 4 Weight gain from entry date to
end of the trial (kg).
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 2 P6 Acupressure versus vitamin B6
Outcome: 4 Weight gain from entry date to end of the trial (kg)
Study or subgroup Acupressure Vitamin B6
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Jamigorn 2007 33 1.5 (1.2) 33 0.8 (0.6) 100.0 % 0.70 [ 0.24, 1.16 ]
Total (95% CI) 33 33 100.0 % 0.70 [ 0.24, 1.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.00 (P = 0.0027)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours vitamin B6 Favours acupressure
Analysis 3.1. Comparison 3 Auricular acupressure versus placebo, Outcome 1 Nausea/vomiting score
(combined Rhodes Index score) on day 6 (3 days after treatment started).
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 3 Auricular acupressure versus placebo
Outcome: 1 Nausea/vomiting score (combined Rhodes Index score) on day 6 (3 days after treatment started)
Study or subgroup Auricular acupressure Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Puangsricharern 2008 (1) 45 7.7 (4.9) 46 11.3 (9.2) 100.0 % -3.60 [ -6.62, -0.58 ]
Total (95% CI) 45 46 100.0 % -3.60 [ -6.62, -0.58 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.34 (P = 0.019)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours acupressure Favours control
(1) Acupressure started on day 3
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Analysis 3.2. Comparison 3 Auricular acupressure versus placebo, Outcome 2 Number of anti-emetic drugs
used on day 6 (3 days after treatment started).
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 3 Auricular acupressure versus placebo
Outcome: 2 Number of anti-emetic drugs used on day 6 (3 days after treatment started)
Study or subgroup Auricular acupressure Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Puangsricharern 2008 (1) 45 0.3 (0.7) 46 0.4 (0.6) 100.0 % -0.10 [ -0.37, 0.17 ]
Total (95% CI) 45 46 100.0 % -0.10 [ -0.37, 0.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.46)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours acupressure Favours control
(1) Acupressure started on day 3
Analysis 4.1. Comparison 4 Acustimulation therapy at P6 point versus placebo, Outcome 1 Weight gain (in
lbs) over 3 week period.
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 4 Acustimulation therapy at P6 point versus placebo
Outcome: 1 Weight gain (in lbs) over 3 week period
Study or subgroup
Nerve
stimulation
therapy Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Rosen 2003 95 2.9 (4.7) 92 1.2 (5.5) 100.0 % 1.70 [ 0.23, 3.17 ]
Total (95% CI) 95 92 100.0 % 1.70 [ 0.23, 3.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.27 (P = 0.023)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours placebo Favours nerve stimulation
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Analysis 4.2. Comparison 4 Acustimulation therapy at P6 point versus placebo, Outcome 2 Dehydration:
occurrences reported.
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 4 Acustimulation therapy at P6 point versus placebo
Outcome: 2 Dehydration: occurrences reported
Study or subgroup
Nerve
stimulation
therapy Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rosen 2003 (1) 3/95 12/92 100.0 % 0.24 [ 0.07, 0.83 ]
Total (95% CI) 95 92 100.0 % 0.24 [ 0.07, 0.83 ]
Total events: 3 (Nerve stimulation therapy), 12 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.26 (P = 0.024)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours nerve stimulation Favours placebo
(1) Time point not specified
Analysis 4.3. Comparison 4 Acustimulation therapy at P6 point versus placebo, Outcome 3 Ketonuria at
the end of the trial.
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 4 Acustimulation therapy at P6 point versus placebo
Outcome: 3 Ketonuria at the end of the trial
Study or subgroup
Nerve
stimulation
therapy Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rosen 2003 4/95 8/92 100.0 % 0.48 [ 0.15, 1.55 ]
Total (95% CI) 95 92 100.0 % 0.48 [ 0.15, 1.55 ]
Total events: 4 (Nerve stimulation therapy), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours nerve stimulation Favours placebo
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Analysis 5.1. Comparison 5 Traditional acupuncture versus placebo, Outcome 1 Mean nausea score on day
7.
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 5 Traditional acupuncture versus placebo
Outcome: 1 Mean nausea score on day 7
Study or subgroup
Traditional
acupunc-
ture Sham acupuncture
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Smith 2002 148 5 (3) 148 5.7 (2.8) 100.0 % -0.70 [ -1.36, -0.04 ]
Total (95% CI) 148 148 100.0 % -0.70 [ -1.36, -0.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.08 (P = 0.038)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours experimental Favours control
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Analysis 5.2. Comparison 5 Traditional acupuncture versus placebo, Outcome 2 Mean dry retching score on
day 7.
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 5 Traditional acupuncture versus placebo
Outcome: 2 Mean dry retching score on day 7
Study or subgroup
Traditional
acupunc-
ture Sham acupuncture
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Smith 2002 148 1.3 (1.4) 148 1.5 (1.8) 100.0 % -0.20 [ -0.57, 0.17 ]
Total (95% CI) 148 148 100.0 % -0.20 [ -0.57, 0.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.29)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours experimental Favours control
Analysis 5.3. Comparison 5 Traditional acupuncture versus placebo, Outcome 3 Mean vomiting score on
day 7.
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 5 Traditional acupuncture versus placebo
Outcome: 3 Mean vomiting score on day 7
Study or subgroup
Traditional
acupunc-
ture Sham acupuncture
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Smith 2002 148 1.4 (2) 148 1.5 (2.2) 100.0 % -0.10 [ -0.58, 0.38 ]
Total (95% CI) 148 148 100.0 % -0.10 [ -0.58, 0.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Not applicable
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Analysis 6.1. Comparison 6 P6 Acupuncture versus placebo, Outcome 1 Mean nausea score on day 7.
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 6 P6 Acupuncture versus placebo
Outcome: 1 Mean nausea score on day 7
Study or subgroup P6 acupuncture Sham acupuncture
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Smith 2002 148 5.4 (3.3) 148 5.7 (2.8) 100.0 % -0.30 [ -1.00, 0.40 ]
Total (95% CI) 148 148 100.0 % -0.30 [ -1.00, 0.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.84 (P = 0.40)
Test for subgroup differences: Not applicable
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Analysis 6.2. Comparison 6 P6 Acupuncture versus placebo, Outcome 2 Mean dry retching score on day 7.
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 6 P6 Acupuncture versus placebo
Outcome: 2 Mean dry retching score on day 7
Study or subgroup P6 acupuncture Sham acupuncture
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Smith 2002 148 1.6 (1.7) 148 1.5 (1.8) 100.0 % 0.10 [ -0.30, 0.50 ]
Total (95% CI) 148 148 100.0 % 0.10 [ -0.30, 0.50 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
Test for subgroup differences: Not applicable
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Analysis 6.3. Comparison 6 P6 Acupuncture versus placebo, Outcome 3 Mean vomiting score on day 7.
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 6 P6 Acupuncture versus placebo
Outcome: 3 Mean vomiting score on day 7
Study or subgroup P6 acupuncture Sham acupuncture
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Smith 2002 148 1.2 (2) 148 1.5 (2.2) 100.0 % -0.30 [ -0.78, 0.18 ]
Total (95% CI) 148 148 100.0 % -0.30 [ -0.78, 0.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.23 (P = 0.22)
Test for subgroup differences: Not applicable
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Analysis 7.1. Comparison 7 Traditional acupuncture versus P6 acupuncture, Outcome 1 Mean nausea score
on day 7.
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 7 Traditional acupuncture versus P6 acupuncture
Outcome: 1 Mean nausea score on day 7
Study or subgroup
Traditional
acupunc-
ture P6 acupuncture
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Smith 2002 148 5 (3) 148 5.4 (3.3) 100.0 % -0.40 [ -1.12, 0.32 ]
Total (95% CI) 148 148 100.0 % -0.40 [ -1.12, 0.32 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.28)
Test for subgroup differences: Not applicable
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Analysis 7.2. Comparison 7 Traditional acupuncture versus P6 acupuncture, Outcome 2 Mean dry retching
score on day 7.
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 7 Traditional acupuncture versus P6 acupuncture
Outcome: 2 Mean dry retching score on day 7
Study or subgroup
Traditional
acupunc-
ture P6 acupuncture
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Smith 2002 148 1.3 (1.4) 148 1.6 (1.7) 100.0 % -0.30 [ -0.65, 0.05 ]
Total (95% CI) 148 148 100.0 % -0.30 [ -0.65, 0.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.66 (P = 0.097)
Test for subgroup differences: Not applicable
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Analysis 7.3. Comparison 7 Traditional acupuncture versus P6 acupuncture, Outcome 3 Mean vomiting
score on day 7.
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 7 Traditional acupuncture versus P6 acupuncture
Outcome: 3 Mean vomiting score on day 7
Study or subgroup
Traditional
acupunc-
ture P6 acupuncture
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Smith 2002 148 1.4 (2) 148 1.2 (2) 100.0 % 0.20 [ -0.26, 0.66 ]
Total (95% CI) 148 148 100.0 % 0.20 [ -0.26, 0.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.86 (P = 0.39)
Test for subgroup differences: Not applicable
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Analysis 8.1. Comparison 8 Ginger versus placebo, Outcome 1 Improvement in nausea (mean change
score) over 4 days of treatment: women available to follow up.
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 8 Ginger versus placebo
Outcome: 1 Improvement in nausea (mean change score) over 4 days of treatment: women available to follow up
Study or subgroup Ginger Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Vutyavanich 2001 32 2.1 (1.9) 35 0.9 (2.2) 100.0 % 1.20 [ 0.22, 2.18 ]
Total (95% CI) 32 35 100.0 % 1.20 [ 0.22, 2.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.39 (P = 0.017)
Test for subgroup differences: Not applicable
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Analysis 8.2. Comparison 8 Ginger versus placebo, Outcome 2 Improvement in nausea (mean change
score) over 4 days of treatment: ITT analysis.
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 8 Ginger versus placebo
Outcome: 2 Improvement in nausea (mean change score) over 4 days of treatment: ITT analysis
Study or subgroup Ginger Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Vutyavanich 2001 32 2.1 (1.9) 38 1.5 (2.8) 100.0 % 0.60 [ -0.51, 1.71 ]
Total (95% CI) 32 38 100.0 % 0.60 [ -0.51, 1.71 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
Test for subgroup differences: Not applicable
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Analysis 8.3. Comparison 8 Ginger versus placebo, Outcome 3 Little improvement in nausea.
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 8 Ginger versus placebo
Outcome: 3 Little improvement in nausea
Study or subgroup Ginger Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Keating 2002 (1) 3/13 8/10 100.0 % 0.29 [ 0.10, 0.82 ]
Total (95% CI) 13 10 100.0 % 0.29 [ 0.10, 0.82 ]
Total events: 3 (Ginger), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.34 (P = 0.019)
Test for subgroup differences: Not applicable
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(1) Event represents less than a 4 point improvement in score
Analysis 8.4. Comparison 8 Ginger versus placebo, Outcome 4 Number of women continuing vomiting at
day 6.
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 8 Ginger versus placebo
Outcome: 4 Number of women continuing vomiting at day 6
Study or subgroup Ginger Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Keating 2002 4/12 8/10 100.0 % 0.42 [ 0.18, 0.98 ]
Total (95% CI) 12 10 100.0 % 0.42 [ 0.18, 0.98 ]
Total events: 4 (Ginger), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.00 (P = 0.046)
Test for subgroup differences: Not applicable
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Analysis 8.5. Comparison 8 Ginger versus placebo, Outcome 5 Spontaneous abortion.
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 8 Ginger versus placebo
Outcome: 5 Spontaneous abortion
Study or subgroup Ginger Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Vutyavanich 2001 1/32 3/35 100.0 % 0.36 [ 0.04, 3.33 ]
Total (95% CI) 32 35 100.0 % 0.36 [ 0.04, 3.33 ]
Total events: 1 (Ginger), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.89 (P = 0.37)
Test for subgroup differences: Not applicable
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Analysis 8.6. Comparison 8 Ginger versus placebo, Outcome 6 Caesarean delivery.
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 8 Ginger versus placebo
Outcome: 6 Caesarean delivery
Study or subgroup Ginger Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Vutyavanich 2001 6/32 4/35 100.0 % 1.64 [ 0.51, 5.29 ]
Total (95% CI) 32 35 100.0 % 1.64 [ 0.51, 5.29 ]
Total events: 6 (Ginger), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.41)
Test for subgroup differences: Not applicable
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Analysis 8.7. Comparison 8 Ginger versus placebo, Outcome 7 Improvement in nausea intensity after
treatment (day 5).
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 8 Ginger versus placebo
Outcome: 7 Improvement in nausea intensity after treatment (day 5)
Study or subgroup Ginger Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ozgoli 2009 (1) 27/32 20/35 100.0 % 1.48 [ 1.07, 2.04 ]
Total (95% CI) 32 35 100.0 % 1.48 [ 1.07, 2.04 ]
Total events: 27 (Ginger), 20 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.36 (P = 0.018)
Test for subgroup differences: Not applicable
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(1) Reported in % improvement per group in text.
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Analysis 9.1. Comparison 9 Ginger versus vitamin B6, Outcome 1 Nausea vomiting score day 3.
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 9 Ginger versus vitamin B6
Outcome: 1 Nausea vomiting score day 3
Study or subgroup Ginger Vitamin B6
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Rhodes Index
Chittumma 2007 61 4.9 (2.1) 62 5.1 (2.4) 49.0 % -0.09 [ -0.44, 0.27 ]
Subtotal (95% CI) 61 62 49.0 % -0.09 [ -0.44, 0.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.63)
2 10 cm VAS
Sripramote 2003 64 3.2 (2.54) 64 3 (2.42) 51.0 % 0.08 [ -0.27, 0.43 ]
Subtotal (95% CI) 64 64 51.0 % 0.08 [ -0.27, 0.43 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
Total (95% CI) 125 126 100.0 % 0.00 [ -0.25, 0.25 ]
Heterogeneity: Chi2 = 0.44, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.99)
Test for subgroup differences: Chi2 = 0.44, df = 1 (P = 0.51), I2 =0.0%
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Analysis 9.2. Comparison 9 Ginger versus vitamin B6, Outcome 2 Post-treatment number of vomiting
episodes: day 3.
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 9 Ginger versus vitamin B6
Outcome: 2 Post-treatment number of vomiting episodes: day 3
Study or subgroup Ginger Vitamin B6
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Sripramote 2003 64 1.1 (2.03) 64 1.1 (1.4) 100.0 % 0.0 [ -0.60, 0.60 ]
Total (95% CI) 64 64 100.0 % 0.0 [ -0.60, 0.60 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 9.3. Comparison 9 Ginger versus vitamin B6, Outcome 3 No improvement in symptoms.
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 9 Ginger versus vitamin B6
Outcome: 3 No improvement in symptoms
Study or subgroup Ginger Vitamin B6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ensiyeh 2009 (1) 6/35 11/34 28.7 % 0.53 [ 0.22, 1.27 ]
Smith 2004 78/146 76/145 71.3 % 1.02 [ 0.82, 1.27 ]
Total (95% CI) 181 179 100.0 % 0.84 [ 0.47, 1.52 ]
Total events: 84 (Ginger), 87 (Vitamin B6)
Heterogeneity: Tau2 = 0.11; Chi2 = 2.08, df = 1 (P = 0.15); I2 =52%
Test for overall effect: Z = 0.56 (P = 0.57)
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(1) Evaluated at follow-up visit one week after start of trial (treatment was for 4 days)
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Analysis 9.4. Comparison 9 Ginger versus vitamin B6, Outcome 4 Spontaneous abortion.
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 9 Ginger versus vitamin B6
Outcome: 4 Spontaneous abortion
Study or subgroup Ginger Vitamin B6 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ensiyeh 2009 2/35 1/34 10.1 % 1.94 [ 0.18, 20.45 ]
Smith 2004 3/146 9/145 89.9 % 0.33 [ 0.09, 1.20 ]
Total (95% CI) 181 179 100.0 % 0.49 [ 0.17, 1.42 ]
Total events: 5 (Ginger), 10 (Vitamin B6)
Heterogeneity: Chi2 = 1.67, df = 1 (P = 0.20); I2 =40%
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Not applicable
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Analysis 9.5. Comparison 9 Ginger versus vitamin B6, Outcome 5 Stillbirth.
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 9 Ginger versus vitamin B6
Outcome: 5 Stillbirth
Study or subgroup Ginger Vitamin B6 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Smith 2004 0/146 3/145 100.0 % 0.14 [ 0.01, 2.72 ]
Total (95% CI) 146 145 100.0 % 0.14 [ 0.01, 2.72 ]
Total events: 0 (Ginger), 3 (Vitamin B6)
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.20)
Test for subgroup differences: Not applicable
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Analysis 9.6. Comparison 9 Ginger versus vitamin B6, Outcome 6 Congenital abnormality.
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 9 Ginger versus vitamin B6
Outcome: 6 Congenital abnormality
Study or subgroup Ginger Vitamin B6 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Smith 2004 3/146 6/145 100.0 % 0.50 [ 0.13, 1.95 ]
Total (95% CI) 146 145 100.0 % 0.50 [ 0.13, 1.95 ]
Total events: 3 (Ginger), 6 (Vitamin B6)
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
Test for subgroup differences: Not applicable
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Analysis 9.7. Comparison 9 Ginger versus vitamin B6, Outcome 7 Antepartum haemorrhage/abruption,
placenta praevia.
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 9 Ginger versus vitamin B6
Outcome: 7 Antepartum haemorrhage/abruption, placenta praevia
Study or subgroup Ginger Vitamin B6 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Smith 2004 5/146 5/145 100.0 % 0.99 [ 0.29, 3.36 ]
Total (95% CI) 146 145 100.0 % 0.99 [ 0.29, 3.36 ]
Total events: 5 (Ginger), 5 (Vitamin B6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Not applicable
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Analysis 9.8. Comparison 9 Ginger versus vitamin B6, Outcome 8 Pregnancy-induced hypertension.
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 9 Ginger versus vitamin B6
Outcome: 8 Pregnancy-induced hypertension
Study or subgroup Ginger Vitamin B6 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Smith 2004 5/146 4/145 100.0 % 1.24 [ 0.34, 4.53 ]
Total (95% CI) 146 145 100.0 % 1.24 [ 0.34, 4.53 ]
Total events: 5 (Ginger), 4 (Vitamin B6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
Test for subgroup differences: Not applicable
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Analysis 9.9. Comparison 9 Ginger versus vitamin B6, Outcome 9 Pre-eclampisa.
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 9 Ginger versus vitamin B6
Outcome: 9 Pre-eclampisa
Study or subgroup Ginger Vitamin B6 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Smith 2004 6/146 4/145 100.0 % 1.49 [ 0.43, 5.17 ]
Total (95% CI) 146 145 100.0 % 1.49 [ 0.43, 5.17 ]
Total events: 6 (Ginger), 4 (Vitamin B6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Not applicable
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Analysis 9.10. Comparison 9 Ginger versus vitamin B6, Outcome 10 Preterm birth.
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 9 Ginger versus vitamin B6
Outcome: 10 Preterm birth
Study or subgroup Ginger Vitamin B6 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Smith 2004 5/146 3/145 100.0 % 1.66 [ 0.40, 6.80 ]
Total (95% CI) 146 145 100.0 % 1.66 [ 0.40, 6.80 ]
Total events: 5 (Ginger), 3 (Vitamin B6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
Test for subgroup differences: Not applicable
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Analysis 9.11. Comparison 9 Ginger versus vitamin B6, Outcome 11 Arrhythmia.
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 9 Ginger versus vitamin B6
Outcome: 11 Arrhythmia
Study or subgroup Ginger Vitamin B6 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chittumma 2007 1/61 0/62 100.0 % 3.05 [ 0.13, 73.40 ]
Total (95% CI) 61 62 100.0 % 3.05 [ 0.13, 73.40 ]
Total events: 1 (Ginger), 0 (Vitamin B6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
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Analysis 9.12. Comparison 9 Ginger versus vitamin B6, Outcome 12 Headache.
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 9 Ginger versus vitamin B6
Outcome: 12 Headache
Study or subgroup Ginger Vitamin B6 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chittumma 2007 0/61 2/62 100.0 % 0.20 [ 0.01, 4.15 ]
Total (95% CI) 61 62 100.0 % 0.20 [ 0.01, 4.15 ]
Total events: 0 (Ginger), 2 (Vitamin B6)
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Not applicable
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Analysis 9.13. Comparison 9 Ginger versus vitamin B6, Outcome 13 Heartburn.
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 9 Ginger versus vitamin B6
Outcome: 13 Heartburn
Study or subgroup Ginger Vitamin B6 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chittumma 2007 8/61 2/62 33.2 % 4.07 [ 0.90, 18.38 ]
Sripramote 2003 6/64 4/64 66.8 % 1.50 [ 0.44, 5.06 ]
Total (95% CI) 125 126 100.0 % 2.35 [ 0.93, 5.93 ]
Total events: 14 (Ginger), 6 (Vitamin B6)
Heterogeneity: Chi2 = 1.03, df = 1 (P = 0.31); I2 =3%
Test for overall effect: Z = 1.81 (P = 0.070)
Test for subgroup differences: Not applicable
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Analysis 9.14. Comparison 9 Ginger versus vitamin B6, Outcome 14 Sedation or drowsiness.
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 9 Ginger versus vitamin B6
Outcome: 14 Sedation or drowsiness
Study or subgroup Ginger Vitamin B6 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chittumma 2007 7/61 11/62 34.2 % 0.65 [ 0.27, 1.56 ]
Sripramote 2003 17/64 21/64 65.8 % 0.81 [ 0.47, 1.39 ]
Total (95% CI) 125 126 100.0 % 0.75 [ 0.48, 1.19 ]
Total events: 24 (Ginger), 32 (Vitamin B6)
Heterogeneity: Chi2 = 0.18, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 1.20 (P = 0.23)
Test for subgroup differences: Not applicable
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Analysis 9.15. Comparison 9 Ginger versus vitamin B6, Outcome 15 Caesarean delivery.
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 9 Ginger versus vitamin B6
Outcome: 15 Caesarean delivery
Study or subgroup Ginger Vitamin B6 Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ensiyeh 2009 4/35 6/34 100.0 % 0.60 [ 0.15, 2.36 ]
Total (95% CI) 35 34 100.0 % 0.60 [ 0.15, 2.36 ]
Total events: 4 (Ginger), 6 (Vitamin B6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
Test for subgroup differences: Not applicable
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Analysis 10.1. Comparison 10 Ginger versus dimenhydrinate, Outcome 1 Drowsiness.
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 10 Ginger versus dimenhydrinate
Outcome: 1 Drowsiness
Study or subgroup Ginger Dimenhydrinate Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Pongrojpaw 2007 5/85 66/85 100.0 % 0.08 [ 0.03, 0.18 ]
Total (95% CI) 85 85 100.0 % 0.08 [ 0.03, 0.18 ]
Total events: 5 (Ginger), 66 (Dimenhydrinate)
Heterogeneity: not applicable
Test for overall effect: Z = 5.89 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 10.2. Comparison 10 Ginger versus dimenhydrinate, Outcome 2 Heartburn.
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 10 Ginger versus dimenhydrinate
Outcome: 2 Heartburn
Study or subgroup Ginger Dimenhydrinate Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Pongrojpaw 2007 13/85 9/85 100.0 % 1.44 [ 0.65, 3.20 ]
Total (95% CI) 85 85 100.0 % 1.44 [ 0.65, 3.20 ]
Total events: 13 (Ginger), 9 (Dimenhydrinate)
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Not applicable
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Analysis 11.1. Comparison 11 Vitamin B6 versus placebo, Outcome 1 Mean reduction in nausea score after
3 days.
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 11 Vitamin B6 versus placebo
Outcome: 1 Mean reduction in nausea score after 3 days
Study or subgroup Vitamin B6 Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Sahakian 1991 31 2.9 (2.4) 28 1.9 (2) 21.2 % 1.00 [ -0.12, 2.12 ]
Vutyavanich 1995 168 3 (2.4) 166 2.1 (3) 78.8 % 0.90 [ 0.32, 1.48 ]
Total (95% CI) 199 194 100.0 % 0.92 [ 0.40, 1.44 ]
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 3.49 (P = 0.00049)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours placebo Favours Vitamin B6
Analysis 11.2. Comparison 11 Vitamin B6 versus placebo, Outcome 2 Number of patients with emesis post-
therapy.
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 11 Vitamin B6 versus placebo
Outcome: 2 Number of patients with emesis post-therapy
Study or subgroup Vitamin B6 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Sahakian 1991 8/31 15/28 42.0 % 0.48 [ 0.24, 0.96 ]
Vutyavanich 1995 61/168 56/165 58.0 % 1.07 [ 0.80, 1.43 ]
Total (95% CI) 199 193 100.0 % 0.76 [ 0.35, 1.66 ]
Total events: 69 (Vitamin B6), 71 (Placebo)
Heterogeneity: Tau2 = 0.25; Chi2 = 4.36, df = 1 (P = 0.04); I2 =77%
Test for overall effect: Z = 0.68 (P = 0.50)
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Analysis 12.1. Comparison 12 Hydroxyzine versus placebo, Outcome 1 No relief from nausea.
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 12 Hydroxyzine versus placebo
Outcome: 1 No relief from nausea
Study or subgroup Hydroxyzine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Erez 1971 18/100 39/50 100.0 % 0.23 [ 0.15, 0.36 ]
Total (95% CI) 100 50 100.0 % 0.23 [ 0.15, 0.36 ]
Total events: 18 (Hydroxyzine), 39 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 6.48 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 12.2. Comparison 12 Hydroxyzine versus placebo, Outcome 2 Spontaneous abortion (1st or 2nd
trimester).
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 12 Hydroxyzine versus placebo
Outcome: 2 Spontaneous abortion (1st or 2nd trimester)
Study or subgroup Hydroxyzine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Erez 1971 4/79 2/36 100.0 % 0.91 [ 0.17, 4.75 ]
Total (95% CI) 79 36 100.0 % 0.91 [ 0.17, 4.75 ]
Total events: 4 (Hydroxyzine), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.11 (P = 0.91)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 12.3. Comparison 12 Hydroxyzine versus placebo, Outcome 3 Perinatal mortality.
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 12 Hydroxyzine versus placebo
Outcome: 3 Perinatal mortality
Study or subgroup Hydroxyzine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Erez 1971 1/79 0/36 100.0 % 1.39 [ 0.06, 33.26 ]
Total (95% CI) 79 36 100.0 % 1.39 [ 0.06, 33.26 ]
Total events: 1 (Hydroxyzine), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 13.1. Comparison 13 Debendox (Bendectin) versus placebo, Outcome 1 No improvement of
symptoms.
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 13 Debendox (Bendectin) versus placebo
Outcome: 1 No improvement of symptoms
Study or subgroup Debendox Placebo Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Geiger 1959 (1) 3/52 20/57 0.16 [ 0.05, 0.52 ]
McGuiness 1971 (2) 12/41 18/40 0.65 [ 0.36, 1.17 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 15 (Debendox), 38 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 0 (P<0.00001); I2 =0.0%
Test for overall effect: Z = 0.0 (P < 0.00001)
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(1) Time point of outcome assessment and duration of study unclear.
(2) Not clear when ”overall response” measured.
Analysis 14.1. Comparison 14 Thiethylperazine versus placebo, Outcome 1 Poor relief from symptoms.
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 14 Thiethylperazine versus placebo
Outcome: 1 Poor relief from symptoms
Study or subgroup Triethylperazine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Newlinds 1964 19/85 36/79 100.0 % 0.49 [ 0.31, 0.78 ]
Total (95% CI) 85 79 100.0 % 0.49 [ 0.31, 0.78 ]
Total events: 19 (Triethylperazine), 36 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.01 (P = 0.0026)
Test for subgroup differences: Not applicable
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Analysis 15.1. Comparison 15 Fluphenazine-pyridoxine versus placebo, Outcome 1 Poor response to
treatment.
Review: Interventions for nausea and vomiting in early pregnancy
Comparison: 15 Fluphenazine-pyridoxine versus placebo
Outcome: 1 Poor response to treatment
Study or subgroup
Fluphenazine-
Pyridoxine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Price 1964 9/37 19/41 100.0 % 0.52 [ 0.27, 1.01 ]
Total (95% CI) 37 41 100.0 % 0.52 [ 0.27, 1.01 ]
Total events: 9 (Fluphenazine-Pyridoxine), 19 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.92 (P = 0.054)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Fluphenazine- B6 Favours placebo
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